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Atherosclerotic cardiovascular disease (ASCVD) is the worldʼs number one 
killer, markedly affecting healthy life years globally, and demanding urgent and 
well-planned strategies to avert and combat the detrimental effects it marks 
upon societies at large. One of the practical approaches to the latter purpose 
would be to enhance preventive strategies by improving risk prediction and risk 
stratification. The aspect that ASCVD is a complex multifactorial disease, how-
ever, impedes straight-forward solutions and requires sturdy endeavours to en-
hance the understanding of the phenotype. The underlying pathology of 
ASCVD is atherosclerosis, an inflammatory condition that develops over many 
years and is often advanced by the time symptoms occur. Extensive research on 
ASCVD has accelerated our knowledge on the epidemiological, molecular and 
genetic aspects of the phenotype, yet the full comprehension of the disease is far 
from complete. 
 Risk prediction guidelines accompanied by risk prediction tools endorsed by 
cardiological societies have been the cornerstone of ASCVD prevention strate-
gies for decades and are widely used in todayʼs clinical setting. While the risk 
prediction tools generally do identify individuals at the highest risk for thera-
peutic interventions, these lack in precision and can misestimate disease risk, 
thereby inaccurately targeting individuals for preventative therapies. More im-
portantly, as the risk estimation of these models relies on the assessment of tra-
ditional phenotypic risk factors, these in reality foretell ASCVD risk based on 
already perturbed molecular pathways and hence lack in providing accurate 
estimation for primordial prevention, that is estimating risk before risk factors 
emerge. 
 One of the current, hotly debated topics regarding the precision and im-
provement of ASCVD risk prediction has centred on the incorporation of gene-
tic information into the daily clinical setting. The scrutiny on the genetic archi-
tecture of ASCVD conducted in recent decades has now resulted in estimates 
that can be of clinical utility and value. Research has hitherto revealed nume-
rous rare and common genetic loci associated with the phenotype, and unveiled 
molecular pathways and trajectories leading to the disease. Moreover, it has 
incited large-scale collaboration projects and propelled the development of 
novel approaches to utilize and combine vast datasets, and new strategies to 
address hypotheses and research questions. 
 Today, we have arrived at the dawn of a paradigm shift that will bring mole-
cular and genetic research at the doorstep of routine clinical practice. This is 
brought about by the plummeting costs in array and sequencing technologies, 
the acknowledgment of the value of integrating different information levels and 
sources in data analysis, and the creation of novel research avenues triggered by 
the detailing of the unravelled genetic findings in different molecular systems. 
In this doctoral thesis, I have aimed to give an overview of the endeavours that 
have set the stage for this transition. Furthermore, I will bring examples on how 
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high-coverage sequencing can advance the genetic interrogation of ASCVD-
related phenotypes and how the utilization of the information contained within a 
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1. REVIEW OF THE LITERATURE 
1.1. Atherosclerotic cardiovascular disease 
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbi-
dity and mortality worldwide, accounting for more than 15 million deaths an-
nually (WHO, 2016). While the prevention and treatment strategies applied in 
routine clinical care, and the attention gained for attaining a healthy lifestyle 
have substantially contributed to the declining ASCVD mortality rates in Euro-
pe, Estonia is still among the top countries with the highest ASCVD incidence 
rates and considered a high-risk country in terms of cardiovascular mortality by 
the European Society of Cardiology (Piepoli et al., 2016).  
ASCVD is a complex multifactorial disease that results from the interplay of 
genetic susceptibility and environmental factors. The root cause of the disease is 
atherosclerosis, a slowly progressive chronic inflammatory condition of the large 
and medium size arteries. It is driven by the infiltration of lipoprotein particles 
into the coronary and carotid arteries due to the dysfunction of the endothelial 
cells that line these vessels. A subsequent inflammatory response leads to the 
formation of atherosclerotic plaques, that consist of macrophage- and vascular 
smooth muscle cell-derived foam cells, apoptotic and necrotic cells and cellular 
debris, and are covered by a collagen, proteoglycans and smooth muscle cells 
containing fibrous cap. Besides obstructing the blood flow, plaques can rupture 
due to intrinsic lytic processes and lack of repair that drive the cap weakening, 
thus causing a thrombotic occlusion of the artery and hence manifesting as myo-
cardial infarction or stroke (Erdmann et al. 2018; Schankman et al., 2015; Khera 
and Kathiresan, 2017; Falk, 2006; Lafont, 2003) (Fig. 1).  
Extensive epidemiological studies conducted in the past decades have es-
tablished a number of risk factors that contribute to the progression of the di-
sease. These include age, sex, smoking status, elevated blood pressure, diabetes, 
obesity and sedentary lifestyle. Increased levels of circulating low-density lipo-
protein cholesterol (LDL-C) and triglyceride-rich lipoproteins, and decreased 
concentrations of high-density lipoprotein cholesterol (HDL-C) have also been 
defined as key clinically attainable biomarkers associated with the disease 
(Khera and Kathiresan, 2017). Knowledge of these risk factors have led to the 
development of phenotypic risk prediction models that are now commonly used 
in routine clinical practice to target those at high risk for lifestyle modifications 





Figure 1. Overview of the progression of atherosclerosis. a) An artery contains three 
layers: tunica intima, lined by a monolayer of endothelial cells; tunica media, containing 
smooth muscle cells embedded in extracellular matrix; and adventitia, consisting of 
immune cells, nerve endings and micro-vessels. b) The progression of atherosclerosis 
starts with the adhesion of leukocytes to the activated endothelial cells, migration of the 
bound leukocytes into intima, and maturation of monocytes into macrophages and 
subsequently into foam cells via the uptake of lipoproteins. c) Atherosclerotic plaque 
progression involves the migration and proliferation of smooth muscle cells, and 
synthesis of extracellular matrix macromolecules such as collagen, elastin and proteo-
glycans that form a fibrous cap that covers the plaque. Extracellular lipids derived from 
apoptotic and necrotic cells accumulate as a necrotic lipid core. d) Thrombosis can 
result from the fracture of the fibrous cap (usually thin and collagen-poor with abundant 
macrophages), leading to the exposure of the pro-coagulant material in the core to 
coagulation proteins in the blood. SMC – smooth muscle cell. (Libby et al., 2011). 
  
  
1.1.1. Genetics of atherosclerotic cardiovascular disease 
Large-scale twin and family studies have estimated the heritability of ASCVD 
to be approximately 50–60% and indicated that family history of the disease in 
a parent or sibling is a strong predictor of the incidence of ASCVD (Murabito et 
al., 2005; Lloyd-Jones et al., 2004; Zdravkovic et al., 2002). This knowledge 
has propelled extensive research efforts for understanding the genetic under-
pinnings of atherosclerosis-driven manifestations, driven largely by the dis-
section of the genetic determinants in families predisposed to premature 
ASCVD and the assessment of the polygenic architecture in large-scale geno-
mic analyses. These endeavours have subsequently motivated functional studies 
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for causality inference and broad collaboration efforts for deepening the com-
prehension of ASCVD pathophysiology. 
 
 
1.1.1.1. Family-based studies 
The initial clues for the genetic component of ASCVD were first reported in the 
late 1930s when the family clustering of increased cholesterol levels and pre-
mature coronary heart disease (CHD) were identified (Müller, 1938). Sub-
sequent studies using linkage analysis narrowed the genetic cause to the LDLR 
gene (encodes the LDL receptor responsible for the hepatic cholesterol-con-
taining LDL particle uptake), and confirmed that the pedigree structures were 
consistent with the autosomal dominant inheritance of a single defective gene 
(Goldmann et al., 2010; Lehrman et al., 1985). Today, familial hypercholestero-
lemia (FH), the monogenic disorder of ASCVD, is considered as one of the 
most common single-gene disorders with the prevalence of 1 in 217 (Benn et 
al., 2016). The main cause of the disease is the dysfunction of the LDL receptor, 
that results in increased LDL-C and cholesterol levels in plasma, and premature 
atherosclerotic progression (Khera and Kathiresan, 2017). Over 1,700 genetic 
variants in the LDLR gene have been linked to FH (Leigh et al., 2017) with 
additional deleterious variants identified in the APOB (hampered binding of 
LDL particles to LDL receptor for uptake (Soria et al., 1989)) and gain-of-
function variants in the PCSK9 gene (increased LDL receptor catabolism (Abi-
fadel et al., 2003)).  
 A separate pathway leading to a monogenic form of ASCVD, that is inde-
pendent from the hampered clearance of cholesterol, has also been acknow-
ledged (Erdmann et al., 2018). A family-based study with functional follow-up 
experiments in mice noted rare deleterious variants in genes related to nitric 
oxide signalling in multiple affected family members with premature myo-
cardial infarction. The genetic variants in GUCY1a3 and CCT2 were functio-
nally associated with diminished ability to generate nitric oxide from endo-
thelial cells, increased platelet activation and arterial thrombosis in mouse 
models (Erdmann et al., 2013). This study underscores the value of conducting 
family-based studies with the potential to pinpoint yet unknown disease trajec-
tories to be functionally tested for disease causation.  
 
 
1.1.1.2. Common variant association studies 
While ample evidence supports the co-segregation of a genetic determinant with 
premature ASCVD within families, the monogenic disorders account for only a 
minority of all ASCVD cases and do not explain the high prevalence of the 
disease in the population at large. Extensive research on the aetiology of 
ASCVD has established that the disease is far more complex with multiple 
pleiotropic pathways contributing to the disease progression. Significant 
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advances in molecular technology and computational capacities have led to 
tremendous progress in understanding the genomic architecture of complex 
diseases. Use of genotyping arrays that capture common genetic variation and 
the advances of haplotype imputation have laid the foundation for genome-wide 
association studies (GWAS). While commercially available genotyping arrays 
enable to ascertain genomic variation in pre-selected sites, usually chosen to 
represent the most informative single nucleotide variants (SNV) within a haplo-
type based on linkage disequilibrium (LD), imputation facilitates the determina-
tion of untyped SNVs based on a common haplotype reference panel built using 
whole-genome sequencing (WGS) data (e.g. 1000 Genomes project (Auton et 
al., 2015)). Essentially, in a genome-wide scan, the relationships between com-
mon genome sequence variations and disease predisposition or trait variation in 
unrelated individuals are systematically surveyed on a genome-wide scale. Each 
variant is tested individually and those, that are found to be significantly more 
frequent in individuals with a trait of interest, indicate genomic regions that 
likely affect the phenotype. The statistical power to detect the associations 
largely depend on the sample size, the distribution of effect sizes and frequency 
of putative causal genetic variants segregating within the population, and the 
LD between the genotyped or imputed genetic variants and true causal variants 
(Visscher et al., 2017; Marchini and Howie, 2010; McCarthy et al., 2008).  
 The common variant search for the phenotype started in 2007, when four 
independent groups with sample sizes ranging from 5,000 to 23,000 individuals 
identified a common variant at the 9p21 locus to be associated with a 30% 
increased risk for ASCVD per copy of the risk allele (Wellcome Trust Case 
Control Consortium, 2007; Helgadottir et al., 2007; McPherson et al., 2007; 
Samani et al., 2007). Subsequent genome-wide scans have consistently re-
plicated this finding demonstrating the strongest signal and effect (Nikpay et al., 
2015; CardioGRAMplusC4D Consortium, 2012; Schunkert et al., 2011), yet the 
causal mechanism, despite ten years of scrutiny, remains uncertain. Rigorous 
interrogation of this association has proposed a number of intertwined hypo-
theses. It is suggested that 9p21 risk variants could alter the activity of two 
nearby cyclin-dependent kinase inhibitors (CDKN2A and CDKN2B), involved 
in regulating cell cycle and cellular proliferation, via modulating the expression 
of non-coding RNA ANRIL that resides in this locus (Holdt et al., 2010; 
Jarinova et al., 2009), or that the expression of these kinase inhibitors is affected 
by interferon--mediated inflammatory signalling (Harismendy et al., 2011). 
Moreover, the effect has also been endowed to the ratio of circular to linear 
ANRIL, whereby the circular form confers protection from atherosclerosis by 
controlling ribosomal biogenesis in vascular smooth muscle cells and macro-
phages (Holdt et al., 2016). Lastly, the latest study utilizing the generation of 
vascular smooth muscle cells from genome edited induced pluripotent stem 
cells (iPSC) of individuals with and without the risk haplotype proposed that the 
risk haplotype might induce a cellular phenotypic switch predisposing vascular 
smooth muscle cells to increased proliferation as well as reduced contraction 
and adhesion (Lo Sardo et al., 2018). It is highly plausible that the causal 
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mechanism in this locus is manifested by the intricate interactions between 
different regulatory elements in the non-coding genome and regulatory mole-
cules in different cell types. Future studies attempting to resolve this mecha-
nistic association in fine detail will prove a major step forward in revealing the 
vast, pleiotropic and highly complex interplay within the noncoding genome 
and across different molecular levels that can lead to the concomitant perturba-
tions of various molecular pathways. 
 Fast-forwarding to this day, markedly larger sample sizes have been used in 
the GWA analyses of ASCVD, substantially broadening the spectrum of the 
genetic associations and linking approximately 160 common genetic loci with 
the disease (van der Harst and Verweij, 2018; Klarin et al., 2017; Nelson et al., 
2017; Nikpay et al., 2015; CardioGRAMplusC4D Consortium, 2012;  Schun-
kert et al., 2011; Coronary Artery Disease Genetics Consortium, 2011). The 
vast majority of the genetic variants, however, are common with minor allele 
frequency (MAF) of >5% in the population and are associated with modest 
increases in ASCVD risk (<10% change in risk per allele). While these loci 
cumulatively explain roughly 30–40% of the disease heritability, these account 
for a far greater proportion of ASCVD heritability than identified rare variants 
combined. Even though the rare variant effects are larger compared to the 
effects of common variants, these are present in a much smaller number of indi-
viduals and therefore explain less of the overall heritability of the disease. 
Furthermore, GWAS results have highlighted different trajectories of the 
disease with pathways linked to lipid metabolism, blood pressure, inflamma-
tion, cellular proliferation, vascular remodelling, vascular tone and nitric oxide 
signalling (Fig. 2). Yet for the majority of the uncovered loci, the exact mecha-
nism leading to the disease remains elusive (Erdmann et al., 2018; Khera and 
Kathiresan, 2017). 
Due to the essence of the GWA study design, the variants identified as most 
significant oftentimes reside within loci spanning several kilobases (kb) encom-
passing multiple genes and are generally in LD with true causal variants. 
Despite sturdy efforts of untangling the causal effects for the identified loci, 
mechanistic associations have been unveiled only for a handful. One of the first 
functionally resolved locus associated with decreased LDL-C concentrations 
(Willer et al., 2008) and CHD risk (Kathiresan et al., 2009) is the non-coding 
region on chromosome 1p31 encompassing genes CELSR2, PCRC1 and 
SORT1. In a series of functional studies, the causal variant was pinpointed to 
rs12740374, where the minor allele creates a new binding site for CCAAT-
enhancer-binding transcription factor (C/EBP) and thereby alters the hepatic 
expression of the SORT1 gene (Musunuru et al., 2010). The overexpression of 
SORT1 results in the decreased secretion of very low-density lipoprotein 
(VLDL) and apolipoprotein B (apoB), and reduced total plasma cholesterol and 
LDL-C levels (Strong et al., 2012). Detailed elucidation of the ADAMTS7 locus 
on chromosome 15 similarly clarified the protective association with ASCVD 
(Schunkert et al., 2011), whereby the minor allele of top variant rs3825807 
affected gene maturation and smooth muscle cell migration in vitro (Pu et al., 
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2013). Moreover, studies on Adamsts7−/− knockout mice highlighted de-
creased atherosclerosis burden and cellular proliferation, and enhanced cell 
repair in response to injury (Bauer et al., 2015; Kessler et al., 2015), making 
ADAMTS7 a potential therapeutic target. Lastly, while a 6p24 locus variant 
rs9349379 within the intron of PHACTR1 was linked with the expression of the 
given gene in vascular tissues, albeit without a plausible biological mechanism 
on atherogenesis progression (Wang and Musunuru, 2018; Beaudoin et al., 
2015), a study using fine-mapping approach, epigenome profiling and CRISPR/ 
Cas9 genome editing using iPSC-derived endothelial cells identified the 
rs9349379 variant to regulate the expression of endothelin 1 gene 600 kb up-
stream (Gupta et al., 2017), previously shown to promote atherosclerosis plaque 
development (Amiri et al., 2004). 
 
 
Figure 2. Genes and molecular pathways linked to the genetic loci associated with 





Importantly, given that ASCVD is a multifactorial disease, multiple GWA ana-
lyses have additionally been conducted for the established risk factors, in-
cluding lipid parameters (Surakka et al., 2015), diabetes mellitus type II 
(Mahajan et al., 2018), smoking (Liu et al., 2019), body mass index (Speliotes 
et al., 2010) and blood pressure (Evangelou et al., 2018). Attention is now being 
centred on unravelling the underlying shared genetic determinants and poly-
genic overlap across these phenotypes. With the development of bioinformatics-
based approaches (e.g. LD Score regression for estimating genetic correlation 
between traits (Bulik-Sullivan et al., 2015), or two-sample mendelian randomi-
zation for causal effect estimation (Hartwig et al., 2016)), summary statistics of 
multiple genomic studies can be leveraged for identifying shared genetic com-
ponents among phenotypes driving atherosclerosis progression and to determine 
their causal effect on ASCVD (Zhu et al., 2018; LeBlanc et al., 2016; van 
Iperen et al., 2016; Bulik-Sullivan et al., 2015). 
 
 
1.1.1.3. Rare variant association studies 
The advent of next-generation sequencing has allowed to assess, whether rare 
variants (MAF <1%) not typically included in genotyping arrays could additio-
nally be ascertained in population-based studies, and facilitated bioinformatics 
and statistical approaches, e.g. gene-based rare variant testing, for novel gene 
discoveries. While in genome-wide scans, a single rare variant is usually under-
powered to yield a statistically significant signal when comparing individuals 
affected by disease to control subjects, aggregating rare variants across a gene 
can improve power. In the latter case, rare variants within genes are combined 
into a genomic unit, thereby enabling the comparison of the aggregate fre-
quencies between affected and unaffected individuals (Guo et al., 2016; Lee et 
al., 2014). Unsurprisingly, in the first gene-based rare variant analysis with ap-
proximately 5,000 premature CHD cases and 5,000 control subjects using 
whole-exome sequencing (WES) data, Do et al. identified the LDLR gene as the 
strongest signal with four-fold increased risk for CHD in 2% of the cases. How-
ever, they additionally identified that carriers of rare non-synonymous variants 
in APOA5 (protein product is a component of VLDL, HDL and chylomicron 
particles (Guardiola and Ribalta, 2017)) were at two-fold increased risk for 
myocardial infarction (Do et al., 2014). Another hypothesis-driven analysis on 
the LPL gene (protein product modulates the clearance of dietary fat from the 
circulation (Mead et al., 2002)) identified that 0.4% of the studied individuals 
with a rare deleterious variant in LPL were at two-fold increased risk for CHD 
and displayed higher triglyceride levels (Khera et al., 2017). 
 Importantly, rare variant analyses have additionally unveiled genetic 
markers that confer protection from the disease. As opposed to gain-of-function 
variants identified in FH cases, two inactivating genetic variants in PCSK9 in 
individuals of African ancestry have been linked to substantially lower LDL-C 
levels and up to 88% reduced risk for CHD (Cohen et al., 2005; Cohen et al., 
 19
2006). Protective low-frequency variants have also been found in ANGPTL4 
and APOC3 (protein products regulate plasma triglyceride levels by inhibiting 
lipoprotein lipase (Lafferty et al., 2013; Zheng et al., 2010) with 11% to 40% 
decreased risk (Stitziel et al., 2016; Dewey et al., 2016; Crosby et al., 2014; 
Jørgensen et al., 2014). A comprehensive study based on imputed array data of 
119,146 Icelanders with reference haplotypes derived from the whole-genome 
sequences of 2,636 Icelanders revealed that a 12-base-pair (bp) deletion in 
ASGR1 leads to the inactivation of the asialo-glycoprotein receptor (trans-
membrane protein that plays a role in the homeostasis of circulating glyco-
proteins) in heterozygous carriers (1% of the study population) and is associated 
with 34% lower CHD risk and lower non-HDL levels (Nioi et al., 2016). This 
study was among the first highlighting the value of deriving a population-
specific reference panel from whole-genome sequences of a representative set 
of a population. This approach benefits the imputation of missing genotypes 
into the genomes of a larger proportion of a specific population with array-
derived genotypes and thus enhances the accuracy of identifying population-
specific low-frequency variants that can putatively lead to the ascertainment of 
novel disease pathways. 
 The discovery of protective variants has instigated intense interest in 
developing potential new drug targets to combat ASCVD. For instance, the 
scrutiny on the effect of inactive variants in PCSK9 resulted in the development 
of monoclonal antibody-based inhibitors. These inhibit PCSK9 by binding to 
the protein with high affinity and thereby demolish the ability of the protein to 
bind to and catabolize the LDL receptor. Clinical studies have shown that the 
PCSK9 inhibitors decrease circulation LDL-C levels by >50%, that is 30% to 
40% more compared to current medical treatment (Schmidt, 2017). Similarly, 
antisense oligonucleotides that mimic the protective variant in APOC3 have 
shown to reduce 70% of triglyceride levels in early-phase studies (Burdett, 
2015). These examples underscore the value of using WES and WGS datasets 
for rare variant discovery, and for unearthing novel putative drug targets that 
can ultimately benefit populations at large. 
 
 
1.2. Atherosclerotic cardiovascular disease risk  
prediction in clinical practice 
Early and accurate identification of individuals at high ASCVD risk is critical 
for effective clinical intervention before these individuals develop overt cardio-
vascular events. Estimating the probabilistic susceptibility of an individual to 
the disease is central to todayʼs clinical decision-making (Khambhati et al., 
2018; Torkamani et al., 2018; Abraham et al., 2016). To this end, several risk 
prediction tools that rely on demographic characteristics, basic health para-
meters, and lifestyle and clinical factors have been constructed in order to target 
risk groups for preventative measures and treatment initiation. Consideration of 
different criteria for risk estimation can, however, lead to differences in the 
 20
proportion of individuals categorized for preventative therapies at a population 
level (Gray et al., 2014). Therefore, to accurately estimate disease risk, effective 
and reliable tools that are rigorously validated before clinical applicability for 
the target population are required. 
 
 
1.2.1. Commonly used risk prediction tools in clinical practice 
The ASCVD prevention guidelines endorsed by the American College of 
Cardiology/American Heart Association (ACC/AHA) (Goff et al., 2014), by the 
European Society of Cardiology jointly with the European Atherosclerosis 
Society (ESC/EAS) (Piepoli et al., 2016) and by the UK National Institute for 
Health and Care Excellence (NICE) (NICE, 2018) are the three major guide-
lines considered in routine clinical practice. While their common aim is to stra-
tify individuals based on risk factors into risk categories, the guidelines differ in 
terms of prediction algorithms, predicted endpoints and risk factors considered 
in companion risk prediction tools, as well as the risk thresholds and LDL-C cut 
points for assignment of therapeutic treatment (Greenland and RO, 2016). 
 The Pooled Cohort Equation (PCE) is the companion tool to the 2013 ACC/ 
AHA Guideline on the Assessment of Cardiovascular Risk to estimate a 10-year 
risk for hard ASCVD (defined as coronary death or non-fatal myocardial 
infarction, or fatal or non-fatal stroke) in individuals of 40–79 years of age. The 
risk factors considered in the score include age, sex, ethnicity, total cholesterol, 
HDL-C, systolic blood pressure, antihypertensive medication use, diabetes and 
smoking status (Table 1). The risk estimates were derived from several large, 
racially and geographically diverse cohorts, including the Atherosclerosis Risk 
in Communities study, the Cardiovascular Health Study, the Coronary Artery 
Risk Development in Young Adults study and the Framingham/ Framingham 
Offspring Study cohorts, and were externally validated on six independent 
study cohorts. The ACC/AHA guidelines advise to consider statin therapy for 
individuals, whose estimated 10-year risk for ASCVD is above ≥7.5% 
according to the prediction tool. Individuals at intermediate risk (10-year abso-
lute risk of 5–7.5%) could be considered for statin therapy for primary 
prevention based on patient preferences or perceived benefit based on additional 
risk factors. Importantly, the ACC/AHA guideline does not endorse a treat-to-
target strategy, i.e. aiming specific HDL-C and LDL-C levels, but instead speci-
fies the appropriate intensity of statin for each risk category (Nayor and Vasan, 
2016; Goff et al., 2014; Stone et al., 2013). 
 NICE recommends the QRISK2 algorithm to estimate a 10-year risk of 
developing a fatal or non-fatal ASCVD event (defined as angina pectoris, myo-
cardial infarction, coronary heart disease, stroke and transient ischaemic attack) 
for individuals aged 25–84 years without diabetes mellitus type I. The con-
sidered risk factors include age, sex, ethnicity, smoking status, systolic blood 
pressure, ratio of total cholesterol and HDL-C, body mass index, family history 
of CHD in a first degree relative <60 years of age, social deprivation index (UK 
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postcode), antihypertensive medication use, and status of rheumatoid arthritis, 
chronic kidney disease, diabetes and atrial fibrillation (Table 1). The score was 
developed on 563 general practices in England and Wales with 2/3 of the 
participants randomly allocated to the derivation dataset and 1/3 assigned to the 
validation dataset. NICE Guidelines recommend statin therapy for primary 
prevention in individuals with diabetes mellitus type II, or in those without dia-
betes, but with an estimated 10-year absolute ASCVD risk of ≥10%. Similarly 
to ACC/AHA guidelines, treat-to-target strategy is not endorsed (NICE, 2018; 
Nayor and Vasan, 2016; Hippisley-Cox et al., 2010). 
 
 
Table 1. Overview of the considered risk factors, predicted endpoints and target popula-
tion of three commonly used risk prediction tools: QRISK2 used in the UK, Pooled 
Cohort Equation (PCE) applied in the US, and Systemic COronary Risk Evaluation 
recommended in Europe. 
QRISK2 (UK) 
fatal and non-fatal 
ASCVD 
40–79 years of age 
PCE (US) 
hard ASCVD 
25–84 years of age without 
DM type I 
SCORE (Europe) 
fatal CVD  
>40 years of age without 
CKD 
age age age 
sex sex sex 
systolic blood pressure systolic blood pressure systolic blood pressure 
smoking status smoking status smoking status 
total cholesterol/HDL-C 
ratio 




ethnicity ethnicity  
diabetes diabetes  
antihypertensive 
treatment 
antihypertensive treatment  
body mass index   
atrial fibrillation   
rheumatoid arthritis   
chronic kidney disease   
family history of ASCVD   
UK postcode  




DM – diabetes mellitus; CKD – chronic kidney disease 
 
 
The Systemic COronary Risk Evaluation (SCORE) was initiated to develop a 
risk scoring system for clinical management of cardiovascular risk in the Euro-
pean clinical practice. It targets individuals above 40 years of age without 
chronic kidney disease and estimates 10-year cardiovascular mortality (opposed 
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to combined fatal and non-fatal events). Sex, age, systolic blood pressure, total 
cholesterol or ratio of total cholesterol and HDL-C, and smoking status are 
considered in the algorithm (Table 1). The risk estimation was derived from a 
pooled dataset of population-based and occupational cohort studies from 12 
European countries, and externally validated on 11 European cohorts. Opposite 
to the US and the UK guidelines, a treat-to-target strategy based on estimates 
extrapolated from clinical trials is applied. Drug intervention is recommended 
for those, whose SCORE-based 10-year fatal ASCVD risk is 5–9.9% and LDL-
C level is ≥2.6 mmol/L (100 mg/dL), or risk ≥10% and LDL-C level  
≥1.8 mmol/L (≥70 mg/dL). Therapy is considered for those, whose SCORE-
based 10-year fatal ASCVD risk is <1% and LDL-C level is ≥4.9 mmol/L  
(190 mg/dL), risk ≥1–4.9% and LDL-C level ≥2.6 mmol/L (≥100 mg/dL), risk 
≥5–9.9% and LDL-C level ≥1.8–2.6 mmol/L (≥70–100 mg/dL), or risk ≥10% 
and LDL-C level <1.8 mmol/L (<70 mg/dL) (Catapano et al., 2016; Nayor and 
Vasan, 2016; Piepoli et al., 2016).  
 
 
1.2.1.1. Efficacy of commonly used risk prediction tools 
Due to the different strategies considered, a number of studies have been con-
ducted to evaluate the predictive ability of these guidelines and companion tools 
on independent cohorts. Interestingly, the results consistently demonstrate over-
estimation of ASCVD risk, thereby predisposing a great proportion of individuals 
for therapeutic intervention (DeFilippis et al., 2017; Defilippis et al., 2015; Demir 
et al., 2015; Kavousi et al., 2014; Mortensen and Falk, 2014; Van Staa et al., 
2014). For instance, a comparison of ACC/AHA and ESC guidelines on 7279 
ASCVD-free individuals aged 40 to 75 years showed that the recommendations 
by these guidelines highly overlapped (95.8%), yet the US guidelines advocated 
statin treatment for  substantially more individuals (58.9%) compared to the ESC 
guidelines (33.0%) (Pavlović et al., 2016). Two studies on more than >40,000 
individuals classified 42% of the individuals for statin treatment according to the 
ACC/AHA guidelines while <15% by the ESC/EAS guidelines (Mortensen and 
Nordestgaard, 2018; Mortensen et al., 2017). 
 The disproportional overestimation of disease risk can partly be attributed to 
the discordance of baseline risk between the scoresʼ derivation and target 
cohorts. The clinically applicable risk scores were developed decades ago on 
cohorts that have hitherto followed the premise of improving lifestyle habits 
and incorporating therapeutic interventions into risk reduction, and thus do not 
translate into similar incidence rates today. With overestimation, a great number 
of individuals can be targeted for unnecessary statin treatment (Kavousi et al., 
2014). On the other hand, setting too high of a threshold for treatment recom-
mendations for primary prevention can miss a great proportion of individuals, 
who later do develop an ASCVD event, thus undermining the main aim of 
clinical risk prediction (Mortensen and Nordestgaard, 2018). Additionally, it 
needs to be considered that treatment benefits are not constant for all indi-
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viduals and may vary markedly among them (Thanassoulis et al., 2016). There-
fore, for improved risk prediction, further steps are required to accurately ascer-
tain individuals for targeted therapy. 
 
 
1.2.2. Diagnosis of familial hypercholesterolemia in  
clinical practice 
Despite the clear genetic cause for FH, the disease is most often diagnosed 
clinically. The phenotype is characterized by clinical and/or family history of 
premature ASCVD, severely elevated plasma LDL-C levels (4.9 mmol/L or 
190 mg/dl) and presence of physical features such as xanthomata, xanthelasma 
and/or corneal arcus (Reiner, 2015). While characteristics required for clinical 
FH diagnosis is generally agreed upon, a universal consensus on the weighting 
of these features is thus far lacking (Berberich and Hegele, 2018). There are 
three formal diagnostic scores that have been proposed and used in the clinical 
setting. These are the US Make Early Diagnosis to Prevent Early Death 
(MEDPED) criteria (Williams et al., 1993), the Simon Broome Register Group 
criteria in the UK (Simon Broome Register Group, 1991) and the Dutch Lipid 
Clinic Network diagnostic score (Defesche et al., 2004). While the latter two 
are similar in terms of considered risk factors and inclusion of genetic testing, 
the MEDPED criteria rely on age, family history and total cholesterol only.  
 Although FH is clinically and genetically well-described, it remains signi-
ficantly under-diagnosed and inadequately treated. Epidemiological studies 
highlight that FH patients are diagnosed late in life, do not receive timely and 
adequate therapy, and display premature subclinical atherosclerotic changes 
(Degoma et al., 2016; Krogh et al., 2016; Perak et al., 2016). Poor performance 
of the diagnostic tools can in part be attributed to the lack of physical features, 
absence of or difficulty in ascertaining family history, or identification of LDL-
C levels lower than the set thresholds (Nordestgaard et al., 2013; Civeira  
et al., 2008; Kee et al., 1993). Khera et al. described that among individuals  
with LDL-C levels above the clinically defined threshold (4.9 mmol/L or  
190 mg/dl), less than 2% harboured an FH-associated variant. However, the 
risk for ASCVD in these individuals was three-fold greater compared to non-
carriers with similarly high LDL-C levels, and two-fold greater in carriers 
compared to non-carriers displaying borderline high LDL-C levels (130 mg/dl or 
3.4 mmol/L) (Khera et al., 2016) (Fig. 3). These results clearly illustrate that 
lifelong exposure to increased LDL-C levels due to a genetic defect drives 
atherosclerosis progression and that the improvement for targeting FH-
associated variant carriers, especially those whose LDL-C levels are below 





Figure 3. Prevalence of FH-associated genetic variants and impact on coronary heart disease 
risk. A. Among severely hypercholesterolemic (LDL-C 190 mg/dl or 4.9 mmol/L) in-
dividuals (5% and 8% in 2 separate study cohorts) less than 2% harboured an FH-
associated variant. B. Risk of coronary heart disease across LDL-C categories in FH-
associated variant carriers and non-carriers. Adapted from (Khera et al., 2016). 
 
 
In light of the shortcomings in diagnosis, high prevalence of the disease, and 
high mortality and morbidity if left untreated, screening for FH is undoubtedly 
warranted (Wonderling et al., 2004). One approach to identify individuals 
affected with FH is genetic testing-based cascade screening. Targeting relatives 
based on genetic testing has shown to not only reduce the average age at which 
individuals with FH are diagnosed and receive timely treatment, but has also 
been confirmed to be cost-effective (Kerr et al., 2017; Lázaro et al., 2017; 
Wonderling et al., 2004). One of the success stories of cascade screening is the 
targeted screening program for FH established in the Netherlands in 1994. As 
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the participation rate in a five-year period yielded 90%, the program resulted in 
the identification of eight family members with the disease-causing variant per 
proband and significantly increased the proportion of carriers receiving treat-
ment (Umans-Eckenhausen et al., 2001). The cost-effectiveness of the Dutch 
targeted screening program was shown subsequently (Wonderling et al., 2004). 
NICE published guidelines for identification and management of FH and re-
commendations for cascade screening in 2008 (DeMott et al., 2008). An ana-
lysis based on the UK screening services data was undertaken in 2017 by Kerr 
et al. It was shown that with testing 1.33 relatives per proband, the cost per 
quality-adjusted life year (QALY) of DNA cascade testing per tested relative 
was estimated to be four times lower compared to the cost-effectiveness thres-
hold commonly used in the UKʼs National Health Service. Furthermore, it was 
speculated that if the number of relatives tested per proband rose to three, the 
cost per QALY would be reduced tenfold (Kerr et al., 2017). Cascade screening 
has also proven to be effective in Australia and Brazil, where each index case 
yielded a further two cases (Bell et al., 2015; Jannes et al., 2015). 
 
 
1.3. Advances in improving atherosclerotic cardiovascular 
disease risk prediction 
In addition to the wide applicability of prediction tools in routine clinical prac-
tice, a number of biomarkers have been proposed for improving ASCVD risk 
prediction. Incorporating non-traditional risk factors, clinically measured bio-
markers for atherosclerosis, or imaging tools results may help to refine estima-
tion for high-risk as well as truly low-risk individuals. Furthermore, these may 
help to tailor intervention for those initially classified as at intermediate risk or 
for whom risk remained uncertain (Khambhati et al., 2018).  
 The proposed non-traditional risk factors and biomarkers include levels of 
high-sensitivity C-reactive protein, haemoglobin A1c, lipoprotein(a), lipo-
protein-associated phospholipase and instrumental measurements of ankle-
branchial index, coronary artery calcium (CAC) score and carotid intima-media 
thickness. While studies have shown their potential additive predictive value for 
ASCVD, the incremental value beyond known risk factors for the most part is 
relatively modest (Folsom, 2013). Furthermore, the genetic associations for the 
majority of these remain to be determined.  
 Lastly, the plethora of GWA studies are paving the way for calculating 




Lipoprotein(a) (Lp(a)) has received wide clinical, molecular and genetic scrutiny 
in the last years, and has emerged as a promising therapeutic target and valuable 





targeted at intermediate risk category. Lp(a) is secreted by the liver and resembles 
an LDL particle, but has additionally a very large glycoprotein, apolipoprotein(a) 
(Apo(a)), covalently linked to the apoB-100 moiety of the LDL particle via a 
disulfide bond (Tsimikas and Hall, 2012; Berglund and Ramakrishnan, 2004; 
Utermann, 1989). Apo(a) is encoded by the LPA gene that consists of ten 
different types of kringle IV domains (KIV-1 to KIV-10), one kringle V domain 
and one protease-like domain. The KIV-1 and KIV-3 to KIV-10 domains are each 
present in a single copy, whereas KIV-2 shows an extensive copy number 
variation (CNV), repeating between 5 to >40 times per chromosome. Each KIV-2 
copy is 5.5 kb in size and consists of two exons of 160 bp and 182 bp in length, 
linked by a large intron (4 kb) and a short intron (1.2 kb) that joins it to the next 
copy (Kraft et al., 1992; Noureen et al., 2015) (Fig. 4). 
 
Figure 4. Structure of lipoprotein(a). Lipoprotein(a) is an LDL-like particle that has an 
ApoA molecule (denoted in red) covalently linked to the apoB-100 moiety of the 
lipoprotein particle. ApoA consists of a protease domain, one kringle V domain and ten 
different types of kringle IV domains, of which kringle IV type 2 is repetitive. Adapted 
from Albers et al., 2007. 
 
 
The plasma concentrations of Lp(a) are determined mainly by the rate of hepa-
tic synthesis of apo(a) (Koschinsky and Marcovina, 2004). Most individuals are 
heterozygous for two different apo(a) isoforms. As the hepatic secretion is 
lower for larger isoforms, the smallest one typically prevails in plasma 
(Nordestgaard et al., 2010). Human Lp(a) concentrations range from <0.1 mg/dl 
to more than 200 mg/dl, thus exhibiting up to three orders of magnitude diffe-
rence among individuals. On average, Africans have two- to three-fold higher 
Lp(a) plasma concentrations than Europeans and most Asian populations 
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(Schmidt et al., 2016). Lp(a) levels have been shown to be genetically deter-
mined by the number of KIV-2 repeats, which correlate with apo(a) size and 
inversely with Lp(a) concentration (Lanktree et al., 2010). The effects from diet 
or lifestyle seem to be rather weak (Kettunen et al., 2016). While the con-
centrations of Lp(a) are generally resistant to statins (Leebmann et al., 2013), 
PCSK9 inhibitor evolocumab has been shown to reduce circulating Lp(a) by 
approximately 25–30% (Raal et al., 2014). 
 The main method for measuring Lp(a) in clinical practice is an immuno-
assay-based method that is sensitive to the entire mass of the Lp(a) particle, 
including apo(a) isoform and lipid content (McConnell et al., 2014). As of now 
there are no commercially available assays that are completely insensitive to the 
variability in particle mass. The lipid parameter can also be quantified as Lp(a)-
cholesterol (Lp(a)-C) by the Vertical Auto Profile (VAP) method. This method 
is based on density gradient ultracentrifugation, whereby the cholesterol con-
centrations of lipoprotein classes are measured simultaneously. After vertical 
rotor-based centrifugation, the content of a centrifuge tube, where the lipopro-
teins have been separated based on their density across the horizontal axis, is 
analysed for cholesterol proportion via the spectrophotometric detection of an 




1.3.1.1. Genetic underpinnings of lipoprotein(a) and association with 
atherosclerotic cardiovascular disease 
Twin studies have estimated the heritability of Lp(a) to be around 90% (Mooser 
et al., 1997; Austin et al., 1992; Lamon-Fava et al., 1991), whereas the GWAS 
explain approximately half of that (Mack et al., 2017). KIV-2 repeats and two 
common SNVs in the LPA gene have been shown to be the main determinants 
of Lp(a) levels (Lanktree et al., 2010). These 2 SNVs that are inversely 
correlated with KIV-2 CNV (Clarke et al., 2009), are rs3798220, located in the 
protease-like domain of LPA, and rs10455872, residing in the long intron of the 
KIV-7 domain, and together explain about 36% of the variation in Lp(a) levels 
in Europeans (Saleheen et al., 2017; Lanktree et al., 2010; Kamstrup et al., 
2009; Clarke et al., 2009). Furthermore, these two variants are associated with 
up to two-fold increased risk for coronary heart disease (Clarke et al., 2009). A 
meta-analysis on five GWA studies (n=13,781) identified 31 SNVs (30 in LPA, 
1 in the APOE gene region), after adjusting for apo(a) isoform size, to be 
significantly associated with Lp(a) concentrations (Mack et al., 2017). A splice 
site variant, rs41272114, linked to decreased Lp(a) levels seems to, however, 
confer protection from ASCVD (odds ratio (OR) 0.84) (Lim et al., 2014).  
 Lp(a) has been established as an independent risk factor for ASCVD, in-
cluding myocardial infarction, cerebral infarction, thrombosis and calcific aortic 
valve stenosis, irrespective of co-existing lipid concentrations, including LDL-C 
(Ergou et al., 2016; Alonso et al., 2014; Thanassoulis et al., 2013; Kamstrup et 
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al., 2009). A mendelian randomization (MR) study on approximately 40,000 
individuals demonstrated that genetically elevated Lp(a) by KIV-2 CNV was 
causally linked with increased risk of myocardial infarction (Kamstrup et al., 
2009). Moreover, elevated Lp(a) levels have been associated with sub-clinical 
disease (higher CAC scores) in individuals with family history of premature 
ASCVD (OR 1.79) (Verweij et al., 2018). A study based on seven randomized, 
placebo-controlled, statin outcome trials of 29,069 individuals showed that 
despite receiving statin treatment, the risk for an ASCVD event persisted in 
those with elevated Lp(a). Furthermore, the Lp(a) concentrations were as-
sociated more strongly with residual ASCVD risk in those assigned statins than 
in individuals allocated placebo (Willeit al., 2018). Moreover, an independent 
GWA study on approximately 10,000 individuals on statin therapy, of which 
3,099 where CHD cases, highlighted the LPA locus as the strongest signal 
associated with adverse events (Wei et al., 2018). These results emphasize the 
requisite for Lp(a)-targeted therapeutics for overall and residual ASCVD risk 
reduction (Willeit al., 2018).  
 In light of the above, it has been hypothesized that Lp(a) measurement could 
provide value for prognostic risk prediction. Importantly, it has been shown that 
adding Lp(a) to established prediction tools reclassified up to 40% of the indi-
viduals initially stratified as intermediate risk group into either higher or lower 
risk categories (Verbeek et al., 2017; Willeit et al., 2014). Furthermore, mea-
surement of Lp(a) has now been added to the ESC/EAS guideline for indi-
viduals at moderate risk or for those with family history of premature ASCVD 
(Piepoli et al., 2016).  
 A number of mechanisms have been proposed explaining the independent 
association between Lp(a) and ASCVD. First, Lp(a) has been shown to be the 
preferential carrier of proinflammatory oxidized phospholipids (oxPL) on apoB-
100 particles in human plasma (Bergmark et al., 2008). The entrapment of 
oxPL-containing particles into the arterial wall could accelerate atherosclerosis 
by inducing an inflammatory response via activating macrophages, and contri-
bute to foam cell formation and smooth muscle cell proliferation (van der Valk 
et al., 2016; Podrez et al., 2002; Zhao and Xu, 2000). Moreover, Lp(a) particles 
could be more avidly retained in the arterial wall by binding to the extracellular 
matrix via the apoB as well as the apo(a) component (Nielsen, 1999). Secondly, 
apo(a) can impair fibrinolysis due to its structural similarity to fibrinolytic pro-
enzyme plasminogen. It is suggested that Lp(a) can induce thrombosis by com-
peting with plasminogen for binding sites on fibrin, thereby reducing the con-
version of plasminogen to plasmin and impairing clot degradation, and through 
inactivation of tissue factor pathway inhibitor that mediates the coagulation 
cascade (Boffa et al., 2004; Deb and Caplice, 2006; Feric et al., 2008). Eluci-
dation of the molecular mechanisms of the Lp(a) particle contributing to athero-
sclerosis and the potential drug targets that could reduce the levels of Lp(a) are 
under intense scrutiny, and will undoubtedly enhance the value of Lp(a) mea-
sure in the clinical setting. 
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1.3.2. Polygenic risk scores 
One of the drawbacks of phenotypic risk scores applied in the clinical setting is 
that they do not provide sufficient discrimination at a younger age when the 
implementation of preventative measures would probably result in the greatest 
long-term benefit. Furthermore, presence of diabetes, smoking history, ab-
normal lipid concentrations or blood pressure levels reflect already altered 
molecular trajectories and perturbations that could be curbed beforehand. One 
of the propositions to circumvent this limitation is to use genomic information 
obtained from GWA studies by calculating polygenic risk scores (PRS). As 
genomic information does not change over the course of a lifetime, one could 
estimate the genetic determinants already at birth, thereby providing value for 
risk prediction far before the clinical risk scores attain predictive capacity at 
later ages. Principally, a PRS is calculated per individual by aggregating the 
estimates obtained for a trait of interest in a GWA analysis into a single 
number. This number is calculated as a weighted sum of the number of disease 
risk variant alleles (𝑋) in each individual, where the risk allele weights (𝛽; variant effect sizes log(OR)) are retrieved from the initial GWA analysis:  
 𝑃𝑅𝑆 = 𝑋 𝛽 , 
 
where 𝑛 is the number of SNVs included in the score. The PRS values tallied 
for each individual are then stratified within a distribution obtained for a sample 
set into distinct risk categories based on percentile rank cut-off values, such that 
each individual will probabilistically be assigned into a specific risk category 
(Torkamani et al., 2018; Khera and Kathiresan, 2017; Chatterjee et al., 2016).  
 The first CHD PRS was composed in 2010 by Ripatti et al. based on 13 
independent ASCVD-associated SNVs. While 20% of the individuals were 
ascertained to be at a 70% increased risk for a CHD event, the PRS did not 
provide sufficient value for clinical utility (Ripatti et al., 2010). A subsequent 
study, where a 46 SNV PRS was calculated using the results from a largest to 
date ASCVD GWAS, yielded similar results, displaying marginal improvement 
of risk prediction beyond traditional risk factors (Ganna et al., 2013). Tada et al. 
demonstrated that a 50 SNV PRS improved CHD risk prediction beyond 
traditional risk factors and family history, and that the individuals in the top 
quintile were at a two-fold increased risk for CHD compared to those in the 
bottom quintile (Tada et al., 2016). Importantly, a UK biobank-based study 
revealed using a 182 SNV PRS that premature ASCVD (≤40 years of age for 
men, ≤45 years of age for women) was also polygenically driven. Although the 
number of cases analysed was small, individuals with premature ASCVD but 
without a rare deleterious dyslipidaemia-associated genetic variant belonged to 
the top PRS quartile associated with a two-fold increase risk for premature 
ASCVD compared to the general population (Thériault et al., 2018). 
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 Mega et al. moved beyond studying the PRS on a representative population-
based cohort and estimated the predictive value of a PRS composed of 27 SNVs 
in the randomized, placebo-controlled studies of statin therapy. They identified 
that individuals in the top quintile of the risk score distribution, being at a 70% 
increased risk for a CHD event, appeared to benefit considerably more from 
statin therapy compared to those in the bottom quintile (Mega et al., 2015). It 
was speculated that those with the highest genomic burden had more plaques 
that statins could stabilize (Thanassoulis et al., 2012). This finding and hypo-
thesis was confirmed by Natarajan et al. using a 57 SNV PRS showing that 
those at the top quintile of risk score distribution had a greater burden of sub-
clinical atherosclerosis and derived greater benefit from statin treatment, com-
pared to all other risk subgroups, despite similar levels of LDL-C lowering by 
statin therapy (Natarajan et al., 2017). These studies clearly show the benefit of 
statin treatment for CHD prevention as well as demonstrate that pinpointing 
genetic markers that are specifically linked to sub-clinical atherosclerosis could 
further help in refining a risk group that would benefit from statin therapy 
initiation the most. 
 Substantial improvement in estimating the predictive value of a PRS on 
ASCVD risk arose from combining tens of thousands to millions SNVs into a 
PRS. This was based on a premise that the consideration of all ASCVD-as-
sociated risk alleles, regardless of their significance level in a GWAS, could 
capture a greater proportion of the genomic burden and hence multiple mecha-
nistic pathways that lead to the disease. Three studies using the latest ASCVD 
GWA analyses (Nikpay et al., 2015; CardioGRAMplusC4D Consortium, 2012) 
and different statistical approaches for risk score calculation, resulted in the 
composition of 49,310, 1.7 million and 6.6 million SNV PRS (Abraham et al., 
2016; Inouye et al., 2018; Khera et al., 2018). Abraham et al. demonstrated that 
the 49,310 SNV PRS was associated with incident CHD events (hazard ratio 
(HR) of 1.5 per 1 standard deviation (SD) increase) independently of es-
tablished phenotypic risk scores and individual CHD risk factors, including 
family history (Abraham et al., 2016). Inouye et al. evidenced that a meta-score 
of 1.7 million SNVs predicted two-fold increased CHD risk for individuals al-
ready on therapeutic interventions when comparing top and bottom quintiles, 
addressing the requirement for continuous targeting of residual disease risk 
(Inouye et al., 2018). Khera et al. showed that a PRS aggregating 6.6 million 
common variants in the UK Biobank-based sample set of 290,000 individuals 
can identify twenty-fold more individuals at comparable three-fold increased 
risk identified in FH-associated variant carriers (Khera et al., 2018). These esti-
mates provide a solid support for determining genomic risk at an early age that 
can be followed up by assessing established risk factors further in life. Assu-
rance for such a strategy stems from the analysis on 55,685 individuals 
demonstrating that among individuals with a high genomic burden of ASCVD-
associated variants calculated on 50 SNVs, those who led a healthy lifestyle had 
a 50% lower 10-year risk of developing a coronary event compared to those 
with unfavourable lifestyle habits (Khera et al., 2016). Furthermore, incorpo-
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rating PRS into clinical practice could benefit initiation of and/or adherence to 
lifestyle modifications and preventative therapies. For instance, disclosure of 
CHD risk estimates incorporating also genetic info on 28 SNVs led to 
significantly lower LDL-C levels at six months follow-up than disclosure of 
risk based on conventional risk factors alone. However, no differences in die-
tary fat intake nor physical activity were noted (Kullo et al., 2016).  
 Altogether, it is fair to say that we are at the dawn of integrating PRS into 
clinical practice and of conveying clinically meaningful risk estimation to those 
whose genomes are enriched in risk alleles. While the prediction tools in-
corporating PRS can facilitate identifying subgroups of individuals who would 
benefit from the prioritization of preventive actions (Torkamani et al., 2018), 
future efforts will help refining these groups more specifically and accurately. 
With knowledge on risk factor-specific and gene-environment interactions 
(Wijmenga and Zhernakova, 2018), and delineation of sub-risk scores based on 
molecular pathways, it is highly likely that therapeutic-specific clinical proto-
cols will eventually start to herald clinically applied precision medicine. 
 
 
1.4. Next steps for refining atherosclerotic cardiovascular 
disease risk prediction 
Assessment of the power of utilizing polygenic risk scores, clinical validation of 
novel biomarkers and refinement of risk prediction tools have and will contri-
bute to the efforts of reducing the global ASCVD burden by targeting primary 
prevention. However, with the use of large-scale cohorts, sophisticated bioinfor-
matics methodologies and data management approaches, and utilization of 
WGS and WES data, a paradigm shift in terms of tackling the complexity of 
ASCVD is transpiring. This will usher the change of focus from cohort-specific 
research endeavours to state-of-the-art advancements, whereby population-
based research will essentially guide the integration of refined biological under-
pinnings and genetic associations into clinical practice.  
 
 
1.4.1. Harnessing biobank information for personalizing 
atherosclerotic cardiovascular disease risk prediction 
Biobank-contained data that hold genetic, molecular and phenotypic informa-
tion on a large number of individuals is now considered as a key resource that 
has the potential of laying the groundwork for precision medicine. Major efforts 
in founding, maintaining and upgrading large-scale and population-based 
biobanks are being undertaken, e.g. the Estonian Biobank (Leitsalu et al., 2015), 
UK Biobank (Bycroft et al., 2018), Geisinger MyCode Community Health 
(Carey et al., 2016), Lifelines (Scholtens et al., 2015), deCODE Genetics 
(Gudbjartsson et al., 2015), Electronic Medical Records and Genomics Network 
(Gottesman et al., 2013), Kaiser Permanente Research Program on Genes, 
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Environment and Health (Kaiser, 2018), and the Million Veteran Program 
(Gaziano et al., 2016). These resources integrate high-quality genomic data with 
electronic health repositories (EHR) with the central aim of tackling genotype-
phenotype associations on a larger scale (Dewey et al., 2016). One of the crucial 
advantages that these initiatives hold is the built of population-specific haplo-
type reference panels from whole-genome sequencing a set of a cohort, that 
enables the imputation of rare and low-frequency variants not captured on 
genome-wide arrays (Mitt et al., 2017; Huang et al., 2015; Deelen et al., 2014) 
and not identified on common haplotype reference panels (1000 Genomes pro-
ject (Auton et al., 2015).  
 The UK Biobank is one of the largest projects that has demonstrated the 
successful collection, and sharing of genetic and clinical information of 500,000 
individuals on a large scale. Furthermore, they now venture to increase its 
content by sequencing the genomes of one million individuals. The initiative 
holds the objective to make its complete datasets as well as results from 
conducted studies fully available (Bycroft et al., 2018). Contrary to capturing 
the resources on multi-ethnic individuals, small countries, such as Estonia and 
the Netherlands, contain information on genetically more homogeneous 
individuals within a more uniform national infrastructure, allowing simpler 
follow-up on individuals and more consistent retrieval of information from 
established EHR (Wijmenga and Zhernakova, 2018). Furthermore, an 
individual-level advantage that stems from these large-scale resources is the 
return of clinically actionable genomic findings to research participants, 
bridging the transition of research information to clinical care. Geisinger 
MyCode Community Health Initiative has started to undertake such a genotype-
first approach based on the pathogenic and likely pathogenic variants from a set 
list of genes associated with monogenic conditions. They have thus far 
disclosed the results to 542 participants and outlined a detailed model for 
clinical reporting of genomic findings (Schwartz et al., 2018).  
 
 
1.4.1.1 Value of electronic health records 
Linking EHR to biobank-contained resources allows to address a wide variety 
of research questions on the full spectrum of health- and disease-related traits, 
enables fine-grained longitudinal analyses for health over time, and offers 
resolution of clusters of diseases and endpoints of interest (Hemingway et al., 
2018). Valuable phenotypic and clinical data can be retrieved from national 
health insurance and regional hospital databases, causes of death and disease-
specific registries. The most prominent use of EHR data is the utilization of 
structured and unstructured data from hospital resources that are usually 
generated during routine clinical care (such as physiological measurements, 
demographic information, clinical blood analyses, imaging results, clinically 
used device data etc.). Structured EHR data are recordings based on fixed 
clinical terminology (Systematized Nomenclature of Medicine Clinical Terms 
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(Shahpori and Doig, 2010)), medical classification for diseases, signs, symp-
toms, abnormal findings, complaints and external causes of injury or diseases 
(International Statistical Classification of Diseases and Related Health Problems 
(ICD, 2016)), surgical procedures (Nordic Medico-Statistical Committee Clas-
sification of Surgical Procedures (NOMESCO, 2011)) and classification of 
active ingredients of drugs (Anatomical Therapeutic Chemical Classification 
System (ATC, 2018)). Patientʼs medical history, discharge summaries and 
imaging reports are usually recorded as unstructured text (Hemingway et al., 
2018).  
 Besides enabling large-scale genome-wide scans in a hypothesis-free manner 
for traits of interest, coupling of EHR with genomic data facilitates also fine-
graining of different phenotypes. For instance, one can ascertain carriers of rare 
deleterious protein truncating variants and detail the phenotype or sub-pheno-
types, and subsequently recall the carriers for additional testing in a clinical 
setting. Second, gene-based testing by aggregating intra-genic rare variants into 
a genomic unit allows to conduct phenome-wide association studies for inter-
rogating novel phenotypes or unidentified biological mechanisms for genes of 
interest. Third, with the use of large-scale population data, true population pre-
valence of a condition can be estimated. And fourth, speedy recruitment of 
individuals harbouring deleterious variants for clinical trials of new therapeutics 
could directly benefit precision medicine (Denny et al., 2013; Rader and 
Damrauer, 2016) (Fig. 5). 
One of the examples of implementing such a strategy is the DiscovEHR col-
laboration, where WES data of 50,726 adult participants of European ancestry 
were coupled to longitudinal EHR of up to 14 years. Each participant was found 
to harbour on average 21 rare predicted loss of function (LoF) SNVs, whereas 
linkage with EHR enabled to confirm the phenotypic consequences for these 
variants. Next, gene-based testing on lipid traits identified novel rare variants, 
for instance in the G6PC gene that encodes glucose-6 phosphatase catalytic 
subunit and has been associated with glycogen storage disease type 1a (Chou et 
al., 2002). Association testing with triglyceride levels revealed that hetero-
zygotes for protein-disrupting variants in the G6PC gene displayed moderately 
increased hypertriglyceridemia. Furthermore, interrogation of 76 clinically 
actionable disease-associated genes linked with 27 medical conditions unveiled 
that 3.5% of the study participants harbour a pathogenic or likely pathogenic 
variant that can be acted upon via therapeutic interventions (Dewey et al., 
2016). A targeted scan for FH in the same sample set revealed that clinical 
diagnosis of FH based on established criteria identifies only a quarter of FH-
associated variant carriers (Abul-Husn et al., 2016). Lastly, in a comprehensive 
phenome-wide association analyses-based study leveraging EHR data and over 
600,000 common variants, disease pairs were constructed on the basis of shared 
genetic components. In addition to confirming the clustering of autoimmune 
diseases (e.g. diabetes type I, rheumatoid arthritis, psoriasis and multiple 
sclerosis), genetic-based networking linked immune-mediated diseases also 
with hyperlipidaemia (Verma et al., 2019). This finding highlights the value of 
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Figure 5. Research approaches of linking EHR information with genomic data (Rader 
and Damrauer, 2016). pLoF - putative loss-of-function.  
 
 
The successful implementation of EHR data for genetic analysis, however, 
faces a number of caveats. As EHR are obtained as a by-product of routine 
clinical care aimed mainly for clinical use, these contain missing values, incor-
rect entries and vast quantities of unstructured free text that contain valuable 
information on pathological findings. Furthermore, absence of data points in 
EHR does not specifically translate into absence of phenotype, but could 
indicate unidentified disease diagnosis. Text mining, natural language pro-
cessing methods and more sophisticated extraction and curation of information 
are being developed to counteract these errors. Altogether, incorporation of 
EHR data in genomic-based research holds the potential for precision medicine 
on a population scale (Denny, 2012; He et al., 2017). 
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1.4.2. Multi-omics approach 
Combination of thousands to millions genomic markers into a PRS to maximise 
the converging effect of multiple pathways driving atherosclerosis progression 
holds great potential for timely identification of individuals at high ASCVD 
risk. However, for deciphering the complex interplay of the disease triggers in 
detail, and delineating the molecular cascades that lead from a potential to 
actual disease manifestation, more elaborated approaches are required. While 
the genomic information constitutes a powerful anchor point for mechanistic 
studies of the pathophysiology of the disease, the single layer of information 
does not capture the full spectrum of molecular effects that jointly and in 
intricate combination manifest as an outcome. Based on current knowledge, it is 
fair to conclude that non-linear and complex interactions and molecular 
cascades occur in atherosclerosis involving simultaneous pathological changes 
in diverse cell types, tissues and organs at multiple molecular levels. The 
technological advances that have broadened the availability, cost-effectiveness 
and quality of genome, epigenome, transcriptome, proteome, metabolome and 
microbiome data are now paving way for amalgamating multiple layers of 
information across different omics domains. Multi-dimensional data integration 
can empower the search for mechanistic drivers underlying ASCVD, help in 
delineating its subtypes, understand the phenotypic variations on different 
molecular levels and identify biomarkers with diagnostic and prognostic value.  
 One of the examples of such a strategy was demonstrated by Björkegren et 
al. who analysed the genomic information and transcriptome data from seven 
disease-relevant vascular and metabolic tissues collected from 600 ASCVD 
cases during coronary artery bypass surgery in the STARNET study. By per-
forming a number of integrative network analyses, key drivers causal for 
regulatory gene networks of CHD interconnected in vascular and metabolic 
tissues were distinguished (Talukdar et al., 2016). Furthermore, regulatory 
SNVs identified in GWA studies for cardiometabolic diseases were more exten-
sively found tissue-specifically or across tissues of CHD-affected individuals 
than in tissue- and disease-unspecific expression studies (Franzén et al., 2016).  
 Despite some notable efforts, the multi-omics field is still in its infancy. The 
main limitations stem from the high complexity within and between individual 
datasets, technical and computational shortcomings in modelling to accurately 
capture true signals, and lack of appropriate data in large enough cohorts from 
multiple time points and different tissues. However, with the joint collabora-
tions between national and international biobanks and clinicians, these data will 
undoubtedly start to emerge in the coming years (Lau and Wu, 2018; Vilne and 
Schunkert, 2018; Arneson et al., 2017; Hasin et al., 2017).  
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2. AIMS OF THE STUDY 
The general aim of the doctoral thesis was twofold. First, to study the predictive 
ability of phenotype-based ASCVD risk estimation. And secondly, to interro-
gate the value of genomics for improving ASCVD risk prediction. 
The objectives of the thesis were as follows: 
1)  Determine and compare the performance accuracy of three commonly used 
and clinically applied ASCVD risk scores in the Estonian population. 
2)  Ascertain the value of high-coverage whole-genome sequencing data for 
broadening the knowledge of clinically measured and clinically meaningful 
ASCVD biomarkers, namely lipoprotein(a) and LDL-cholesterol. 
3)  Evaluate the implications of genomics-guided identification of individuals at 
high ASCVD risk (genetically predisposed to familial hypercholesterolemia) 




3. RESULTS AND DISCUSSION 
3.1. Performance of phenotypic risk scores in  
a high ASCVD risk setting (Ref. I) 
Today, the identification of individuals at increased ASCVD risk relies mainly 
on clinically applied phenotypic risk scores that facilitate the estimation of 
oneʼs absolute 10-year risk for developing an ASCVD event based on es-
tablished risk factors. Those identified at the highest risk are targeted for thera-
peutic interventions to prevent the onset of an adverse event. There are three 
main commonly used risk scores: Pooled Cohort Estimation endorsed by the 
ACC/AHA in the US (Goff et al., 2014), SCORE by the ESC/EAS in Europe 
(Piepoli et al., 2016) and QRISK2 by the NICE guidelines in the UK (NICE, 
2018). Despite their uniform aim, these vary in terms of predicted outcomes, 
algorithms used for risk calculation and risk factors considered, and further-
more, have been shown to overestimate the actual risk for developing an 
adverse ASCVD event, thereby predisposing a proportion of individuals for 
unnecessary treatment (DeFilippis et al., 2017; Defilippis et al., 2015; Demir et 
al., 2015; Kavousi et al., 2014; Mortensen and Falk, 2014; Van Staa et al., 
2014). This inaccuracy is mainly attributed to the difference in incidence rates 
between the risk score derivation cohorts (usually sample sets from developed 
Western populations comprised decades ago) and the risk score target cohort. 
As Estonia is considered a high-risk country in Europe in terms of ASCVD 
incidence rates, the first objective was to assess the predictive ability of the 
three mainly used phenotypic risk scores and compare their performance on 
targeting individuals at high ASCVD risk for therapeutic interventions. 
 
 
3.1.1. Description of cohort and materials 
The performance accuracy of three commonly applied risk scores, PCE, 
QRISK2 and SCORE, was evaluated on the Estonian Biobank cohort of 51,603 
individuals (Leitsalu et al., 2015). Follow-up data on ASCVD incidence and 
mortality were obtained based on linked information to the Estonian Health 
Insurance Fund database (EHIF, 2018) and the Estonian Causes of Death 
Registry (Causes of Death Registry, 2018). As the median follow-up time was 
7.8 years and more than 70% of the individuals had seven-year follow-up data 
available, the score-specific events were censored at 7 years and the original 
scores of 10-year risk were modified to obtain 7-year risk estimates. Based on 
the guideline-specific criteria, 4,356, 7,191 and 3,987 individuals were eligible 
for calculating the risk estimates of PCE, QRISK2 and SCORE, respectively 
(Fig. 1 in Ref. I). The mean age of the study sample was 40.8 years and 64.1% 
were women (S.Table 2 in Ref. I). Cox proportional hazard models were fitted 
for each outcome with the 7-year risk score estimate as the only covariate. 
Calibration was assessed by standardized incidence ratios (SIR, expected 
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number of events divided by observed number of events) and discrimination by 
Harrellʼs C-statistic. To illustrate the implications of risk prediction, three cate-
gories of recommendations for statin treatment were comprised based on the 
ACC/AHA (Goff et al., 2014), NICE (NICE, 2018) and ESC (Piepoli et al., 
2016) guidelines, and applied on a uniform subset of individuals (n=3,729, 
between the age range of 40–70 years and without diabetes mellitus type I or II 
or chronic kidney disease). 
 
 
3.1.2. Performance accuracy of phenotypic risk scores 
During the seven-year follow-up, 220 hard ASCVD events (PCE outcome), 671 
ASCVD events (QRISK2 outcome) and 94 ASCVD events (SCORE outcome) 
occurred in the score-specific subsets (Table 2 in Ref. I). Based on SIRs 
calculated for evaluating calibration, PCE (SIR 1.03, 95% confidence interval 
(CI) 0.90 – 1.18) and SCORE (SIR 0.99, 95% CI 0.81 – 1.21) performed 
accurately, predicting 3% more hard ASCVD events and 1% less ASCVD 
deaths than observed, respectively. QRISK2, however, severely underestimated 
the risk (SIR 0.52, 95% CI 0.48 – 0.56), predicting approximately 50% less 
events than observed (Fig. 6; Table 2 in Ref. I). The latter result could partly 
stem from the inaccuracy of considering soft endpoints (e.g. angina pectoris), 
that lack strict diagnostic criteria opposite to hard endpoints (e.g. myocardial 
infarction or ASCVD death). In regards to discrimination, PCE (C-statistic 
0.778) was inferior to QRISK2 (C-statistic 0.812) and SCORE (C-statistic 
0.865) (Table 1 in Ref. I), demonstrating that the latter two risk scores per-
formed more accurately in terms of predicting higher risk for those who 
developed an endpoint than those who did not. 
Figure 6. Calibration plots with SIRs demonstrating the performance of risk scores in 
different risk quintiles over the 7-year follow-up. 
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Notably, the risk estimates for individuals with and without events greatly over-
lapped, such that among those who experienced an adverse event, approxima-
tely a quarter of men and third of women were categorized into low or moderate 
risk category (generally considered cut-off of 5%) (S.Fig. 1 in Ref. I). While 
statin treatment recommendations were relatively similar between the guide-
lines, varying from 57% (ACC/AHA) to 36% (SCORE) for men and 27% 
(ACC/AHA) to 10% (SCORE) for women, target groups for whom statins 
could be considered varied greatly. While 14% of men and 7% of women could 
be considered for statin treatment based on the ACC/AHA guidelines, 49% of 
men and 35% of women were targeted for treatment consideration based on the 





Figure 7. Statin treatment recommendations according to the ASCVD prevention 
guidelines on a uniform subset of individuals (n=3,729, between the age range of 40–70 
years, and without diabetes mellitus type I or II or chronic kidney disease). 
 
 
These observations permit several important conclusions. First, phenotypic risk 
scores do perform sufficiently well in a high-risk population, however, up to a 
third of individuals who will develop an adverse event are misclassified as 
moderate or low-risk. Secondly, while individuals were targeted similarly for 
therapeutic intervention across the guidelines, statins could be considered 
additionally for 49% of the individuals by the ESC guidelines. This marks a 
great percentage of the population for whom risk remains ambiguous. Thirdly, 
consideration of soft outcomes for and incorporation of a wide variety of risk 
factors into risk prediction does not translate into more efficacious predictive 
ability of a risk score, as seen for the QRISK2 estimates. Altogether, these 
results highlight the need for further improvement of ASCVD risk prediction. 
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This holds especially true to a high-risk population setting, where improved 
strategies and policies for decreasing ASCVD incidence rates are anticipated. 
   
 
3.2. Value of high-coverage whole-genome sequencing for 
dissecting the genetic underpinnings of ASCVD-associated 
lipid parameters (Ref. II, III) 
An important aspect that needs to be borne in mind is that the discrimination of 
ASCVD risk according to phenotypic risk scores is based on already actualized 
perturbations (abnormal lipid parameter or blood pressure levels, or presence of 
concomitant diseases). In order to improve the ascertainment of individuals at 
high ASCVD risk before they actually develop overt events and moreover, 
before they develop changes in clinically measurable quantifiable biomarkers, 
further advances are needed. Knowing that ASCVD has its genetic basis, one 
can scrutinize the genetic foundation of the disease and its risk factors, and 
identify associations that can additionally carry prognostic value. While exten-
sive research has been conducted in large-scale cohorts based on imputed geno-
typing arrays for ASCVD and ASCVD-related traits, these have generally 
resulted in the identification of putative associations without revealing true 
causality. High-coverage sequencing information, however, does offer a reliable 
platform for dissecting the genomic landscape of ASCVD-related traits with the 
potential to precisely pinpoint clinically meaningful genetic markers. 
 Lipoprotein(a), Lp(a), serves as a perfect example for this kind of endeavour 
due to its high heritability noted in twin studies (Austin et al., 1992; Lamon-
Fava et al., 1991) and solid associations with ASCVD incidence (Ergou et al., 
2016; Kamstrup et al., 2009). Lp(a) is an LDL particle-like plasma lipoprotein 
that has a large glycoprotein apo(a) attached to it. The latter is encoded by the 
LPA gene, containing a large highly polymorphic CNV of the kringle IV type 2 
domain (KIV2-CN). The CNV and SNVs in the LPA locus have been 
associated with Lp(a) concentration in plasma and ASCVD risk (Mack et al., 
2017; Lanktree et al., 2010; Kamstrup et al., 2009). Due to the complex nature 
of the gene and the strong established basis for genetic causality, WGS data for 
ancestrally distinct cohorts was exploited to investigate the full spectrum of the 
genomic variation affecting Lp(a) concentrations and furthermore, to interrogate 
the causality for ASCVD. 
 A comprehensively studied (Surakka et al., 2015; Willer et al., 2013; Teslo-
vich et al., 2010; Kathiresan et al., 2008) strong predictor of ASCVD risk, 
namely LDL-C, was similarly studies based on WGS-derived genotypes in 
ancestrally distinct cohorts for locus discovery. 
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3.2.1. Description of cohort and materials 
To dissect the genetic landscape of Lp(a), deep-coverage (30X) WGS data of 
8,392 individuals (2,284 Estonians from the Estonian Biobank (Leitsalu et al., 
2015), 2,690 Finns from the Finland FINRISK study (Vartiainen et al., 2000) 
and 3,418 African Americans from the Jackson Heart study from the NIH/ 
NHLBI Trans-Omics for Precision Medicine program (Taylor et al., 2005) were 
used (Fig. 1 in Ref. II). The sample genotypes were called separately for the 
African American cohort and jointly for the Estonian and the Finnish cohort 
according to Best Practices (Tan et al., 2015; van der Auwera et al., 2013). 
KIV2-CN in the LPA gene was estimated with Genome STRiP (Handsaker et 
al., 2011) and quantified for each individual as the sum of the KIV2 allelic copy 
number across both chromosomes.  
 While the Lp(a) parameter was not quantified for the Finnish sample set with 
WGS, an imputation model was developed based on their WGS and WES data 
for imputing the KIV2-CN into the array data of 27,344 individuals. This was 
done based on least absolute shrinkage and selection operator in a 4MB window 
around LPA and across high-quality (imputation quality >0.8) variants with 
MAF >0.1% available in the Finnish imputation dataset. This resulted in a 61-
variant model, explaining 60% of the variation in genotyped KIV2-CN.  
 Lp(a) parameter measurements were available either as Lp(a), measured for 
Finns and African Americans with an immunoassay-based method, or as Lp(a)-
C, quantified for Estonians and African Americans with the VAP method. 
Association analyses were carried out with both or either measurement where 
applicable. Both Lp(a) measurements were available for the African Americans, 
displaying moderate correlation (r=0.46) (S.Fig. 5 in Ref. II). Median Lp(a) 
levels in African Americans (median (interquartile range) 46 (24–79) mg/dL) 
were approximately ten times higher than in Finns (5 (2–10) mg/dL), while the 
Lp(a)-C distributions were similar between Estonians (7 (5–9) mg/dL) and 
African Americans (7 (5–11) mg/dL) (S.Table 3 in Ref. II). All study partici-
pants had provided written and informed consent in accordance with the 
respective institutional ethics review board for each of the participating study 
cohort (Fig. 1 in Ref. II). 
 For LDL-C analyses, jointly called genotypes of 30X WGS data according 
to Best Practices (Tan et al., 2015; van der Auwera et al., 2013) from the 
Framingham Heart Study (n=4,064), the Jackson Heart Study (n=3,247) and 
Old Order Amish (n=1,083), as well as from the Finland FINRISK Study 
(n=1,165) and the Estonian Biobank (n=2,255) were studied together with the 
individual WGS dataset of the Multi-Ethnic Study of Atherosclerosis (MESA; 
n=4,510) (Fig. 1 in Ref. III). Conventionally measured LDL-C values were 
used, with statin effect taken into account by dividing by 0.7 as implemented 
previously (Peloso et al., 2014). The mean (SD) age was 51 (15 years) and 8669 
(53%) were women. Thirty-six per cent of the participants were of non-
European ancestry.   
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3.2.2. Genetic interrogation of Lp(a) 
The strongest genetic signal for Lp(a) has been shown to lie in the LPA gene 
locus and specifically as the CNV of the KIV2 repeat (Lanktree et al., 2010). In 
this analysis, the KIV2-CN solely explained 18% to 26% of Lp(a) variation and 
14% of Lp(a)-C variation across ethnicities. The distribution of KIV2-CN 
differed slightly between African Americans (mean 38.5 (SD 7.4)) and Euro-
peans (mean 43.7 (SD 6.2)), ranging between 12–85 copies, and were overall 
negatively associated with Lp(a)-C (-0.05 SD/CN, p = <1×10−61) and Lp(a)  
(-0.07 SD/CN, p = <1×10−190) (Fig. 3 in Ref. II). When centring only on the 
LPA locus (1MB window around the gene), 770 variants for either of the Lp(a) 
parameter reached the genome-wide significance level, of which five showed 
independent and ethnic-specific association for Lp(a)-C, and 43 for Lp(a) 
(S.Fig. 15a,b in Ref. II). On average, LPA locus genetic variants yielding a 1 SD 
increase in Lp(a) resulted in a 0.48 SD increase in Lp(a)-C. Furthermore, two 
known LPA LoF variants (rs41272114 (p = 8×10−77), rs143431368 (p = 
2×10−26) (Kyriakou et al., 2014; Lim et al., 2014) and one novel LoF variant 
(rs199583644 in exon 28 only observed in African Americans (MAF 0.28%,  
p = 3×10−13) showed an association with the Lp(a) parameter. 
 When widening the search to common variants (MAF >0.1%) genome-wide, 
three loci for Lp(a)-C at LPA (rs140570886, p = 3.3×10−30), CETP (rs247616,  
p = 6.1×10−10) and SORT1 (rs12740374, p = 1.0×10−21), and two for Lp(a) at 
LPA (rs6938647, p = 4.7×10−129) and APOE (rs7412, p = 1.3×10−23) were 
identified when conditioned on KIV2-CN. As the lead variants in the SORT1 
and APOE locus, and in the CETP locus have previously been associated with 
LDL-C and HDL-C respectively, conditional analyses on these lipid parameters 
were performed. Whereas the association for the SORT1 and the APOE locus 
were not substantially altered, the association in CETP disappeared (Fig. 8; 
S.Fig. 9 in Ref. II and Fig. 4a,b in Ref. II). Gene-based burden testing on rare 
(MAF <1%) coding or non-coding variants did not pinpoint significant KIV2-
CN-independent associations. 
Next, to ascertain whether any genetic variants affect the relationship 
between KIV2-CN and Lp(a)-C or Lp(a) concentrations, variant-by-KIV2-CN 
interaction analyses at a 4MB window around LPA was performed. Three inde-
pendent variants yielded genome-wide significance across ethnicities 
(rs13192132, p = 1.73×10−15, rs1810126, p = 6.84×10−14, rs1740445, p = 
6.35×10−9). The variant rs13192132 tags the top hit in the Estonian-specific 
interaction analysis, a 3-base deletion (r2 = 0.88), that resides 7,508 bases 
downstream of the LPA transcription start site and overlies H3K4me3 and 
H3K27ac peaks associated with active transcription based on the adult liver 
regulatory annotations from the Roadmap Epigenome Project (Kundaje et al., 
2015) (S.Fig. 21A in Ref. II). 
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Figure 8. Manhattan plots of meta-analysed single variant associations of A) Lp(a)-C 
and B) Lp(a). Associations (betas in SD and 95% CI) for top variants at C) the SORT1 






3.2.3. Inter-ethnic differences in genetic determinants of Lp(a) 
and heritability estimates 
While the latest array-based GWAS estimated the heritability of Lp(a) to be 
49% (Mack et al., 2017), WGS-based estimation yielded 85% for Lp(a) and 
52% for Lp(a)-C in African Americans, and 75% for Lp(a) in Finns and 75% 
for Lp(a)-C in Estonians (Fig. 4d in Ref. II). 
 To dissect any inter-ethnic genetic differences, effects of LPA locus variants 
attaining sub-threshold significance (p = <1×10−4) in either ethnicity for Lp(a) 
and Lp(a)-C were compared, yielding correlation for Lp(a)-C to be 0.38 and for 
Lp(a) to be 0.16 (S.Fig. 16 in Ref. II). Moderately associated (p = <1×10−2) LPA 
locus variants largely private in African Americans (MAF <0.1% in Finns) had 
larger absolute effects across MAFs compared to such variants observed in both 
ethnicities (p = 3×10−32). Furthermore, an LPAL2 intronic variant at the LPA 
locus (rs192873801) yielded significant yet opposing inter-ethnic effect  
(+0.80 SD with MAF 2.8% in African Americans and -0.61 SD with MAF 
2.7% in Finns), likely indicating influences from haplotype structure or gene-





Figure 9. LPAL2 intronic variant rs192873801 with significant heterogeneity across 
ethnicities. Shown are boxplots by cohort for A) Finns (FIN) and B) African Americans 




3.2.4. Phenotypic consequences of the genetic determinants of 
LPA on ASCVD 
To assess causality for ASCVD, MR analysis based on the Finnish imputed data 
of 1056 incident CHD cases and 21,207 controls were conducted. In a MR 
study, genetic variants associated with a modifiable exposure, risk factor, 
biomarker or biological intermediate (in this case Lp(a)) are used to estimate the 
causal relationship between the variable and a clinically relevant outcome. It is 
based on the premise that alleles of genetic determinants are randomly allocated 
during human gamete formation and are nonmodifiable, and therefore ensure 
lifelong exposure and mitigate concerns about reverse causation. Hence, if a 
variable has a causal association with a disease, the genetic determinants of the 
variable should also associate with the disease to the extent predicted by the 
size of the effect of the genetic variant on the intermediate risk factor and the 
size of the effect of the risk factor on the disease (Musunuru and Kathiresan, 
2019; Emdin et al., 2017). In this study, three different genetic instruments were 
composed: 1) PRS, comprised of the sum of the KIV2-CN-adjusted variant 
effects from LD-pruned variants in a 4MB window around LPA with sub-
threshold significance (P = <1×10−4; 339 variants); 2) KIV2-CN; 3) PRS + 
KIV2-CN combined. Each genetic instrument was normalized such that 1 unit 
increase in the score was equal to 1 SD increase in Lp(a). The PRS, KIV2-CN 
and PRS + KIV2-CN score explained 30%, 18% and 47% of Lp(a) variance, 







1.36 per Lp(a) SD, p = 7.6×10−8) compared to PRS + KIV2-CN (HR 1.25 per 
Lp(a) SD, P = 7×10−7) or KIV2-CN alone (HR 1.13 per Lp(a) SD, p = 0.076) 
and compared to the effect of measured Lp(a) on incident CHD risk (HR 1.16,  
p = 3.71×10−3) (Fig. 10; Fig. 7a in Ref. II). These results suggest that know-
ledge of LPA variant class genotypes may provide valuable information on 
cardiovascular risk beyond circulating Lp(a) levels.  
 
Figure 10. Associations (HR and 95% CI) of incident coronary heart disease and 
myocardial infarction with the Lp(a) measurement and with genetic instruments among 
the genotyped and imputed FIN individuals. 
 
 
Altogether, the comprehensive interrogation on the full genomic spectrum of 
Lp(a) parameters highlights the value of analysing high-coverage WGS data in 
different ethnicities. WGS allowed to capture a great proportion of Lp(a) 
heritability, identify common and unique genetic determinants across and speci-
fic to different ethnicities, and ascertain the added value of estimating trait-
associated SNVs for ASCVD causality. Importantly, knowledge of these gene-
tic determinants provides valuable information for ASCVD risk prediction in 
addition to the biomarker level alone. 
 
 
3.2.5 Dissection of the genetic basis of LDL-C variation across 
ancestrally distinct populations 
The common variant search for LDL-C based on high-coverage sequencing data 
resulted in the ascertainment of seven previously identified (Surakka et al., 
2015; Willer et al., 2013; Teslovich et al., 2010; Kathiresan et al., 2008) and 
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three novel loci, covering 697 variants at genome-wide significance. Important-
ly, conditional analyses in ancestrally distinct cohorts revealed a low-frequency 
haplotype specific to African Americans in the LDLR gene locus with variants 
in the first intron of LDLR, in the LDLR promoter and within the enhancer 4 kb 
upstream from the LDLR transcription start site in strong LD (r2 = 0.8). This 
haplotype was associated with 28 mg/dl or 0.72 mmol/L lower LDL-C levels. 
While analyses of rare coding variants pinpointed genes that have previously 
been associated with monogenic dyslipidaemia disorders (LDLR, APOB, 
PCSK9, APOE), non-coding variant investigation did not detect any signals.  
 The incremental value of using WGS information for a genome-wide scan of 
a trait of interest does not yet facilitate the identification of novel putatively 
causal associations due to small sample sizes. However, it does allow to con-
fidently unveil ethnically distinct genomic determinants, that are usually missed 
or identified with low confidence in genotyping array-based analyses that utilize 
a common haplotype reference panel for imputation. With the increasing 
availability of WGS data for different cohorts and built of sample set-specific 
haplotype reference panels for imputing whole-genome array datasets, WGS-
based genome-wide scans will undoubtedly start to unravel distinct common 
and rare putatively causal variants of ASCVD-related phenotypes. 
 
 
3.3. Genomics-guided approach for identifying individuals 
at high ASCVD risk for clinical management (Ref. IV) 
High-coverage sequencing information lends more confidence in genome-wide 
scans to identifying true genetic underpinnings of a trait of interest compared to 
imputed array-derived datasets, which merely unravel causal variant containing 
genomic chunks. However, the phenotypic-driven analyses hold an intrinsic 
bias that stems from the definition of selection criteria for ascertaining the trait 
of interest and can therefore fundamentally dilute the signal of association. This 
is especially true for qualitative traits (e.g. disease outcomes), where the 
affected status could be difficult to ascertain and usually relies on clinically 
meaningful yet biologically less coherent classification systems. To overcome 
this issue, one can apply the reverse approach and start the selection process 
from genetic information. The subsequent determination of genotype-associated 
phenotypes or sub-phenotypes can facilitate causal inference analysis, study of 
biological heterogeneity and assessment of health outcomes on an individual 
level. With acknowledging the valuable resources contained within the Estonian 
Biobank, the latter approach (termed “recall-by-genotype” or RbG) on a 
clinically actionable singe-gene disorder, namely FH, was applied.  
 While FH is genetically and clinically well-described, it remains signifi-
cantly underdiagnosed and inadequately treated (Nordestgaard et al., 2013). 
Individuals affected by this disorder have significantly increased LDL-C levels 
and a substantially greater risk for experiencing myocardial infarction at a 
young age (Khera et al., 2016). As the disease arises mainly due to a single rare 
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deleterious variant that hampers the hepatic clearance of LDL particles, high-
coverage sequencing information provides an optimal platform for determining 
the individuals harbouring a causal variant. In light of the above, the strategy 
was to identify rare deleterious variants in well-known FH-associated genes 
(LDLR, APOB, PCSK9) using WGS and WES datasets, re-contact individuals 
who harbour those variants, and detail their phenotypic expression and clinical 
management via cascade screening and clinical evaluation. 
 
 
3.3.1. Description of cohort and materials 
FH-associated variants were ascertained in high-coverage sequencing data 
available for 10% of the Estonian Biobank cohort (4,776 individuals of 52,274 
participants) (Leitsalu et al., 2015). WGS data was available for 2,420 
individuals and WES data for 2,356 individuals. Rare (MAF <0.5%) LoF or 
deleterious missense variants in LDLR or PCSK9, or in the LDL receptor 
binding domain of APOB were ascertained in individuals whose untreated 
baseline LDL-C level was ≥4.0 mmol/L. Baseline lipid parameters (i.e., avail-
able already at the biobank prior to conducting the study) for the WGS subset 
had been measured with either the conventional enzymatic colorimetric or with 
the VAP method, and for the WES subset with the conventional method only. 
The effect of statin treatment in individuals, who had self-reported use at 
baseline lipid measurement, was taken into account by dividing LDL-C value 
by 0.7, as implemented previously (Peloso et al., 2014) (termed “statin-
adjusted”). The project was approved by the Research Ethics Committee of the 
University of Tartu  and complies with the Declaration of Helsinki. 
 
 
3.3.2. Overview of the recall-by-genotype study design and 
clinical management of FH-associated variant carriers 
A total of 11 distinct FH-associated variants in three FH-associated genes (9 in 
LDLR, 1 in APOB and 1 in PCSK9) were identified in 27 probands in hetero-
zygous state (S.Table 4 in Ref. IV). While an invitation to join the study was 
sent to all 27 individuals, 21 (mean age 47.1 (SD 15.9), 9 were female) 
responded and were scheduled for an appointment with a clinical cardiologist 
and a clinical genetics specialist. At the initial appointment, probands were 
explained the details of the project and signed an informed consent form. Next, 
probandsʼ clinical and family history (up to three generations) was ascertained, 
presence of physical features common for FH (tendon xanthomata, xanthelasma 
and corneal arcus) were assessed, and 50 ml of fasting blood from a peripheral 
vein for biochemical measurements and for a DNA-based confirmation of the 
genetic finding was drawn. If the proband had not experienced an ASCVD 
event prior to the study, investigations for subclinical atherosclerosis were 





media thickness assessment and exercise electrocardiogram). During the second 
visit, all probands received feedback on their genetic and clinical results, and 
were provided guidance regarding treatment and lifestyle modifications. 
Furthermore, all carriers were guided to engage their first- and second-degree 
relatives in cascade screening. The clinical management of relatives followed 
the same approach as for the probands (S.Fig. 1 in Ref. IV). 
 Of 112 invited family members, 64 relatives (57%, mean age 46.6 (SD 
17.1), 52% were female) joined the study. Only those family members, who 
carried the variants (n=20) and had not experienced a clinical ASCVD event 
(n=17), were subjected to instrumental investigations. Altogether, the RbG 
approach with cascade screening resulted in the identification of 41 carriers, 
highlighting great interest of the subjects to participate in a genomics-guided 
study (78% of the probands and 76% of the invited families engaged) (Fig. 11; 
Fig. 1 in Ref. IV, Table 1 in Ref. IV). 
Figure 11. Overview of the recall-by-genotype approach for familial hypercholesterole-




3.3.3. Clinical evaluation of FH-associated variant carriers 
LDL-C concentrations varied from 3.22 mmol/L to 11.56 mmol/L (mean  
5.78 mmol/L (SD 2.05)) among carriers not on treatment (n=28). Statins had 
been prescribed for 19 carriers (46%), however, 13 (32%) of the 41 adhered to 
treatment, while one was taking over-the-counter lipid-lowering supplements. 
Importantly, LDL-C levels had not been lowered to the target level of  
2.6 mmol/L recommended for FH cases without ASCVD according to the ESC 
guidelines (Catapano et al., 2016) in any of the 13 on treatment. The LDL-C 
values ranged from 3.89 mmol/L to 9.10 mmol/L (mean 5.79 mmol/L (SD 
1.41), statin-adjusted). The effect of FH-associated genetic variants on LDL-C 
levels was interrogated in 41 FH-associated variant carriers and 978 non-
carriers for whom WGS data and conventionally quantified lipid measurements 
were available using a linear mixed model. LDL-C value was increased on 
average by 2.33 mmol/L (SD 0.18, p = 1.55×10–21) in FH-associated variant 
carriers (n=41), compared to those without an FH-associated variant (n=978). 
Despite the significantly increased LDL-C levels in carriers, pronounced 
overlap in LDL-C distributions was noted between the two groups (Fig. 12; Fig. 
2. in Ref. IV).  
 
Figure 12
carriers (n=41, mean LDL-C 5.78 mmol/L, SD 1.85) and non-carriers (n=978, mean 
LDL-C 3.56 mmol/L, SD 0.98). The LDL-C level was increased by 2.33 mmol/L  
(SD 0.18) in individuals harbouring an FH-associated variant compared to non-carriers. 












no (n=978, mean=3.56 mmol/L, SD=0.98)
yes (n=41, mean=5.78 mmol/L, SD=1.85)
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In regards to diagnostic criteria commonly considered in clinical FH diagnosis, 
6 individuals (15%) reported positive family history of premature ASCVD in a 
first-degree family member, and only two carriers (5%) displayed a visible 
physical symptom (corneal arcus). The presence of sub-clinical ASCVD was 
ascertained via imaging-based phenotyping. Four FH-associated variant carriers 
(10%) had experienced an ASCVD event prior to the study, (mean age 73.5 (SD 
11.6), 2 were female), twenty (49%) displayed sub-clinical disease (mean age 
50.5 (SD 12.8), 9 were female, mean statin-adjusted LDL-C 6.31 (SD 1.76)), 
and fourteen (34%) did not (mean age 36.2 (SD 8.9), 6 were female, mean 
statin-adjusted LDL-C 4.55 (SD 1.06)). Burden of atherosclerosis could not be 
ascertained in three individuals (7%) as they declined the instrumental investi-
gation procedures (S.Table 5 in Ref. V).  
 Of 20 individuals with sub-clinical atherosclerosis, five had plaques in 
carotid arteries and 19 had CAC >0. To assess, whether the atherosclerotic 
burden was pronounced in those with sub-clinical disease, the CAC scores of 
the 19 individuals were compared with the expected CAC scores distribution 
among those without symptomatic clinical ASCVD (2,503 men and women of 
Caucasian ethnicity from the MESA sub-cohort (McClelland et al., 2006)). 
Sixteen carriers (84%) were complete outliers in terms of the expected age- and 
sex-specific CAC scores determined in ASCVD-free individuals, while three 
participants fell within the expected distribution range. However, among the 
latter three, two had demonstrable plaques in carotid arteries, indicating the 
presence of sub-clinical disease (Fig. 13; Fig. 3 in Ref. IV).  
These results permit several clinically valuable conclusions. First, lack of 
physical symptoms in variant carriers and substantial overlap in LDL-C levels 
between carriers and non-carriers denote under-performance of clinically 
applied diagnostic criteria. Secondly, low statin use and LDL-C levels not 
lowered with treatment to the target level commended by the ESC guidelines 
(Catapano et al., 2016) highlight unmet clinical management of FH cases. 
Third, pronounced clinical and sub-clinical disease among 59% of the variant 
carriers conforms with the disease pathology, whereby a genetic defect pre-
disposes to the premature progression of atherosclerosis due to the lifelong 
exposure to increased LDL-C levels. And fourth, high heterogeneity in clinical 
expression, even among individuals with the same FH-associated variant, and 
lack of sub-clinical disease among younger participants (34%) necessitate 
further study for pinpointing potential modifying genetic variants and assess-
ment of the effect of global genomic burden, and the refinement of a sub-group 




Figure 13. The CAC scores of FH-associated variant carriers with sub-clinical disease 
and CAC >0 (n=19) (filled coloured circles) in comparison with the distribution of CAC 
scores in the MESA sub-cohort of Caucasian ethnicity and without symptomatic clinical 
ASCVD and treated diabetes. The rectangles represent the expected CAC score 
distribution between the 25th and 75th percentile in the MESA sub-cohort for every age 
and for men (blue) and women (red) separately, with age on the x-axis and CAC score 
on the y-axis. While 16 individuals were not expected to have subclinical ASCVD, 
three individuals did (indicated with black circles). However, the 61-year-old female 
and the 54-year-old female displayed plaques in carotid arteries. 
 
 
3.3.4. Clinical management of FH-associated variant carriers 
After clinical and imaging-based phenotyping, 37 individuals (90%) were 
diagnosed with FH. While three (7%) carried an FH diagnosis before partici-
pating and twenty-one (51%) were reclassified from having non-specific hyper-
cholesterolemia to having FH, thirteen (32%) had completely gone unre-
cognized by the medical system (Fig. 14A; Fig. 4A in Ref. IV). Four (10%) need 
further assessment for confident disease diagnosis. Moderate-intensity statin 
treatment was initiated for fourteen (34%), treatment was up-titrated for eleven 
(27%), left unchanged for two (5%) and not prescribed for six (14%). Eight 
participants (20%) either had contraindications or declined (Fig. 14B; Fig. 4B in 
Ref. IV). The pronounced clinical yield demonstrates the power of genomics-
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guided disease management and the value of initiating the search for affected 
individuals within a healthcare-orientated population-based biobank with the 
potential to impact clinical management of affected individuals. 
 
Figure 14. (A) Disease diagnoses and (B) statin treatment in FH-associated variant 




This doctoral thesis aimed to provide an overview of the status quo of the 
genomic research on ASCVD. With acknowledging the burden of the disease 
on human health, substantial endeavours have been made for understanding the 
disease aetiology, by identifying epidemiological factors that accelerate the 
disease progression, and by unravelling the genetic and molecular under-
pinnings that influence the disease initiation and outcome. Today, we recognize 
the complexity of the phenotype and acknowledge the requisite for fine detail 
analyses for piecing the phenotype together. These undertakings facilitate the 
improvement of ASCVD risk prediction strategies, such that more elaborate 
approaches for clinical utility can be developed.  
 The current approach applied in todayʼs clinical setting to target those at 
increased ASCVD risk is based on the assessment of traditional risk factors. 
The evaluation of the predictive ability of the commonly used prediction 
models revealed that the companion tools of ASCVD prevention guidelines do 
work sufficiently well in Estonia, however, do not target high risk individuals 
for treatment uniformly. While the commonly applied clinical strategy is 
beneficial for avoiding disease incidence, it does not always result in definite 
prevention, since the assessment of traditional risk factors reflects the identifi-
cation of already perturbed disease trajectories. To this end, the proposition to 
utilize genetic information has gained wide attention. Detailed analysis based 
on high resolution genomic data allows to unravel valuable information that can 
be assessed before molecular perturbations occur. The comprehensive inter-
rogation of the genetic underpinnings of a highly heritable ASCVD biomarker, 
lipoprotein(a), in African-Americans and Europeans based on high-coverage 
sequencing data facilitated to capture a great proportion of lipoprotein(a) 
heritability, identify common and population-specific genetic determinants, and 
assess the causal impact of the parameter on ASCVD incidence. This study 
serves as an example demonstrating that the knowledge of the genetic determi-
nants of an ASCVD biomarker provides additional value to the mere clinical 
measurement.  
 The final study outlined in the thesis represents the example of bridging 
genetic information with routine clinical practice. With identifying individuals 
harbouring rare deleterious variants predisposing to familial hypercholestero-
lemia (monogenic form of premature ASCVD) within a population-based bio-
bank and detailing their phenotype in the clinical setting, the genotype-first 
approach did not only prove to be feasible and to significantly improved the 
clinical management of high-risk individuals, but additionally highlighted 
diagnostic and treatment gaps as well as underscored the heterogeneity of the 
phenotype. This study represents one of the first implementations of the 
genomics-guided strategy within a national healthcare system and demonstrates 
that the integration of genomic data contained in a population-based biobank 
into routine clinical practice has the potential to transform ASCVD risk pre-
diction and enhance precision prevention strategies. 
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SUMMARY IN ESTONIAN 
Geeniinfo väärtus südame-veresoonkonnahaiguste  
riski hindamisel 
Aterosklerootiline südame-veresoonkonnahaigus (ASVH) on peamiseks sure-
muse põhjuseks maailmas. Et tagada haiguse eelsoodumusega ja haigust põde-
vatele indiviididele õigeaegne ja tõhus ennetusmeede ja/või ravi, tuleb prakti-
lisest seisukohast suunata fookus eeskätt efektiivsete ja täpsete ennetus- ja 
ennustusstrateegiate arendamisele. Lihtsate ja kohe kliinilises praktikas kasutust 
leidvate meetmete rakendamist raskendab aga tõik, et tegemist on kompleksse 
geneetilistest ja keskkonnateguritest mõjutatud haigusega. Selle peamiseks 
tekkepõhjuseks on ateroskleroos  krooniline aeglase kuluga põletikuline hai-
gus, mille sümptomid avalduvad tihtipeale alles siis, kui haigus on moleku-
laarselt juba oluliselt progresseerunud.  
 Tänases kliinilises praktikas on kardioloogiliste eeskirjade raames välja-
töötatud riskimudelid ASVH riski hindamise ja kliinilise käsitluse nurgakiviks. 
Need mudelid hindavad fenotüübiliste riskitegurite alusel ASVH kliiniliste 
avaldumisvormide tekke või nendesse suremise kümne aasta riski. Kuna algo-
ritmid on töötatud välja aga aastakümneid tagasi kogutud kohortide andmetel, ei 
pruugi mudelites kasutatud statistikud vastata tänastele haiguse riskifaktorite 
tunnustele ega haigusjuhtude esinemissagedusele. Seda eeskätt seetõttu, et 
nendel samadel kohortidel põhinevad epidemioloogilised uuringud on suuresti 
ajendanud viimaste aastakümnete ASVH ennetusstrateegiaid ning soodustanud 
elustiili muutuste olulisuse rõhutamise ning ravistrateegiate edendamisega 
kliiniliste avaldumisvormide langustendentsi. Nimetatud aspekt on põhjuseks, 
miks riskimudelite omavahelised võrdlused näitavad lääne riikide kohortidel 
haigusriski märkimisväärset ülehindamist ning ravi määramist oluliselt rohke-
matele indiviididele kui vaja. Kuna Eesti on ASVH-sse suremuse osas Euroopas 
esimeste hulgas, võrreldi enim kasutatud riskialgoritmide ennustustäpsust Eesti 
Geenivaramu kui kõrge ASVH esinemissagedusega kohordis. Kuigi analüüsi-
tulemuste kohaselt hindasid riskiskoorid kliiniliste avaldumisvormide riski 
üldplaanis hästi, klassifitseeriti kolmandik haigusjuhuga indiviide aga madala-
masse riskikategooriasse ning pea pooltele jäi ravi määramine ebatäpseks. Olu-
line kitsaskoht fenotüübiliste riskiskooride rakendamisel ilmneb selles, et need 
mudelid hindavad riskitegurite üleslugemisega tegelikkuses molekulaarsel 
tasandil juba toimunud muutusi, see tähendab metaboolsete radade ja vereringe-
süsteemi häirumist (näiteks kolesterooli ja/või vererõhu kõrgenenud tase, 
suitsetamise kestus, diabeedi kaasesinemine). Seega leevendatakse praeguse 
strateegia kasutamisel pigem patoloogia progresseerunud kulgu, kui pärsitakse 
või ennetatakse molekulaarsete mehhanismide häirumist varases staadiumis.  
 Üheks võimalikuks riskiskooride täpsemaks muutmise lahenduseks paku-
takse tunnuse geneetilise eripära arvestamist. ASVH geneetilisi seoseid on 
viimastel kümnenditel uuritud peamiselt detailsete perekonnauuringutega, kus 
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on tuvastatud haiguse monogeenseid vorme (näiteks perekondlikku hüper-
kolesteroleemiat) põhjustavaid kõrge efektisuurusega mutatsioone, ning 
genoomiülestel kiipidel põhinevate seoseuuringutega, millega on hinnatud 
fenotüübi polügeenset komponenti. Kuigi genoomiülesed assotsiatsiooniuurin-
gud võimaldavad haigusseoselisi genoomipiirkondi efektiivselt tuvastada, jääb 
konkreetsete põhjuslike geenivariantide kindlaksmääramine kiipide tagasihoid-
liku resolutsiooni taha. Kõrge kattuvuse ja resolutsiooniga kogu genoomi 
järjestusandmestik võimaldab selles vallas olulist edasiarengut. Nimetatud 
lähenemist kasutati kliinilises praktikas mõõdetava ASVH biomarkeri lipo-
proteiin(a) geneetiliste seoste analüüsimiseks. Kolme eri populatsiooni põhine 
analüüs lubas hinnata biomarkeri päritavuse määra, tuvastada nii populat-
sioonide üleseid kui ka spetsiifilisi geneetilisi assotsiatsioone ning määrata 
biomarkeri ja ASVH põhjuslikku seost. Analüüsitulemused tugevdavad para-
meetri geneetilise komponendi hindamise vajalikkust, ennustades ASVH kliini-
lisi avaldumisvorme kliinikumis mõõdetud väärtustest paremini.  
 Näiteks, kuidas geneetilise informatsiooni kasutamine kliinilises praktikas 
rajab teed personaalsele meditsiinile, on Eesti Geenivaramu genotüübi-põhisel 
tagasikutsumisel baseeruv perekondliku hüperkolesteroleemia kliinilise käsit-
luse uuring. Nimelt tuvastati populatsiooni-põhise biopanga kõrge resolutsioo-
niga järjestusandmestikus harva geneetilise variandi, kuid kõrge haigusriskiga 
(perekondlikku hüperkolesteroleemiat põdevad) indiviidid ja kaskaaduuringu 
kaudu samu variante kandvad lähisugulased ning hinnati geneetilise nõustamise 
ja detailise kardioloogilise profiilimisega nende kliinilist käsitlust. Kui pooltel 
haigusvariandi kandjatest tuvastati varasemalt kindlaksmääratud kõrgenenud 
kolesterooli taseme põhjuseks geeniviga perekondliku hüperkolesteroleemiaga 
seotud geenis, siis oli kolmandik nendest jäänud meditsiinisüsteemis täielikult 
märkamata. Lisaks haiguse aladiagnoosimise ja alaravitavuse kinnitamisele, 
näitas töö veel olemasolevate diagnostiliste kriteeriumide ebatäpsust ning 
haiguse fenotüübilise pildi heterogeensust.  
 Käesoleva doktoritöö peamine eesmärk oli anda ülevaade, kuidas tänane 
ASVH riski hindamine kliinilises praktikas on muutumas ja kuidas geneetilise 
informatsiooni kaasamine igapäeva kliinilistesse otsustesse seda edendada 
võiks. Jätkuv uurimistöö, seda nii metodoloogiliste edasiarenduste, fenotüübi 
etioloogia täpsema mõistmise, erinevate molekulaarsete tasemete lõimimise 
ning suuremahuliste kohortide ja biopankade andmete integreerimisega medit-
siinisüsteemi, lubab selles vallas olulist edasiarengut ning vähendada haigusest 
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